A Study on the Pattern of Fungal Infections and Clinical Profile in Immunocompromised Patients with Special Reference to Characterisation and Molecular Study of Candida Species In A Tertiary Care Hospital by Akilamani, M
 A STUDY ON THE PATTERN OF FUNGAL INFECTIONS AND 
CLINICAL PROFILE IN IMMUNOCOMPROMISED PATIENTS 
WITH SPECIAL REFERENCE TO CHARACTERISATION AND 
MOLECULAR STUDY OF CANDIDA SPECIES IN A TERTIARY 
CARE HOSPITAL 
 
 
Dissertation submitted for 
M.D. MICROBIOLOGY BRANCH – 1V 
DEGREE EXAMINATION 
 
 
 
THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY 
CHENNAI – 600 032 
TAMILNADU 
 
 
MAY 2019 
 
 
CERTIFICATE 
 
 
 This is to certify that this dissertation titled “A STUDY ON THE   
PATTERN OF FUNGAL INFECTIONS AND  CLINICAL PROFILE IN   
IMMUNOCOMPROMISED   PATIENTS  WITH SPECIAL   REFERENCE   TO 
CHARACTERISATION   AND MOLECULAR STUDY OF CANDIDA SPECIES 
IN A TERTIARY CARE HOSPITAL” is a bonafide record of work done by 
Dr.M.AKILAMANI during the period of March 2017 to February 2018 under 
the guidance of Prof.Dr.C.P.RAMANI .M.D., Professor of Microbiology, 
Institute of Microbiology , Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai - 600003, in partial fulfillment of the 
requirement of M.D. MICROBIOLOGY Degree Examination of The Tamilnadu  
Dr.M.G.R. Medical University to be held in May 2019. 
 
 
 
 
 
Dr. R.JAYANTHI, M.D.FRCP (Glas) 
DEAN 
Madras Medical College & 
Rajiv Gandhi Govt. General Hospital, 
Chennai – 600003. 
Dr.J.EUPHRASIA LATHA, 
    M.D.DGO 
Director, 
Institute of Microbiology 
Madras Medical College & 
Rajiv Gandhi Govt. General Hospital, 
Chennai – 600003. 
 
  
DECLARATION 
 
 
 I, Dr.M.AKILAMANI Post Graduate , Institute of Microbiology, Madras 
Medical College, solemnly declare that the dissertation titled “A STUDY   ON 
THE   PATTERN OF FUNGAL INFECTIONS AND  CLINICAL PROFILE IN   
IMMUNOCOMPROMISED   PATIENTS  WITH SPECIAL   REFERENCE   TO 
CHARACTERISATION   AND MOLECULAR STUDY OF CANDIDA SPECIES 
IN A TERTIARY CARE HOSPITAL” is the bonafide work done by me at 
Institute of Microbiology, Madras Medical College under the expert guidance and 
supervision of Prof. Dr. C.P. RAMANI M.D., Professor, Institute of 
Microbiology, Madras Medical College. The dissertation is submitted to the Tamil 
Nadu Dr.M.G.R Medical University towards partial fulfillment of requirement for 
the award of M.D., Degree (Branch IV) in Microbiology. 
 
 
 
Place: Chennai 
 
Date:                           Dr.M.AKILAMANI 
 
 
 
 
 
Signature of the Guide 
Prof.Dr.C.P.RAMANI M.D.,  
Professor, 
Institute of Microbiology 
Madras Medical College, Chennai - 600 003. 
 
  
ACKNOWLEDGEMENTS 
 
 I wish to express my sincere thanks to Dr.R.Jayanthi, M.D.FRCP (Glas), 
Dean, Rajiv Gandhi Government General Hospital & Madras Medical College, 
Chennai-3 for permitting me to use the resources of this institution for my study. 
 
I express my thanks to Dr.J.Euphrasia Latha, M.D.DGO, Director, 
Institute of Microbiology for her guidance and support. 
 
 Sincere thanks to Former Professor Dr.Mangala Adisesh M.D., Institute 
of Microbiology for her constant encouragement and support during this work. 
 
 I owe my heartfelt gratitude and sincere thanks to my guide  
Dr. C.P.Ramani, M.D., Professor, Institute of Microbiology for  her valuable 
suggestions,guidance,constant support, motivation and encouragement throughout 
this study. 
 
 My Sincere thanks to  Dr.C.Margaret M.D., Professor ,Department of 
Hematology, Dr.Mayil vahanan.M.D ,Director, Institute of Internal Medicine  
and Dr.Kalaichelvi .M.D.DM., Professor and  Head of  the  Department, 
Department of Medical Oncology  for their constant encouragement and support 
during my study. 
 
 I would like to thank all my Professors Dr.S.Thasneem Banu M.D., 
Dr.U.Umadevi M.D., and  Dr.R.VANAJA M.D., for their support during this 
study.  
         I extend my gratitude to my co-guide Dr.C.NITHYA M.D.,Assistant 
Professor, Institute of Microbiology for his valuable guidance and constant 
support in this study. 
 
 I extend my gratitude to   my former co-guide Dr.R.DEEPA 
M.D.,Assistant Professor, Institute of Microbiology for her valuable guidance and 
constant support in this study. 
 
 I wish to extend my thanks to our Assistant Professors 
Dr.Lakshmipriya.N M.D.DCH., Dr.K.G.Venkatesh M.D., DR.R.Kesavan 
M.D.DCH,Dr.P.ShanmugapriyaM.D.,Dr.C.Nithya M.D., Dr.J.PadmaKumari 
M.D., Dr.S.Vinotha M.D.,Dr. B.Gomathi Manju M.D.,  for their support. 
 
 I wish to extend my thanks to our  former Assistant Professors 
Dr.N.Rathna priya M.D., Dr.K.Ushakrishnan M.D., Dr.Sripriya.C.S M.D., 
Dr. David Agatha M.D., Dr.B.Natesan M.D.DLO., for their support. 
 
 I would like to extend my thanks to all my postgraduate colleagues and 
technicians for their constant support and help in this study. 
 
 I am thankful to my dear parents, inlaws for their unconditioned love, 
sacrifice and constant emotional support. I thank my husband Dr.K.Selvam M.S, 
and my son S.Jayaviswa for his constant motivation, emotional support and help 
in  completing the dissertation work.   
 
 I would like to thank the Institutional Ethics Committee ,Madras Medical 
college for approving my study . 
 
     Last but not least, I would like to thank the patients participated in this 
study for their co-operation and support. 
 
TABLE OF CONTENTS 
 
Sl. 
No. TITLE Page No. 
1 INTRODUCTION 1 
2 AIMS &OBJECTIVES 3 
3 REVIEW OF LITERATURE 4 
4 MATERIALS & METHODS 32 
5 RESULTS 51 
6 DISCUSSION 78 
7 SUMMARY 84 
8 CONCLUSION 87 
9 COLOUR PLATES 88 
10 BIBLIOGRAPHY  
 
APPENDIX- I  ABBREVIATIONS 
 
APPENDIX- II  STAINS,REAGENTS, MEDIA  
 
ANNEXURE - I    CERTIFICATE OF APPROVAL 
 
ANNEXURE - II   PROFORMA  
 
ANNEXURE - III   PATIENTS CONSENT FORM 
 
ANNEXURE - IV  INFORMATION SHEET 
 
ANNEXURE - V  MASTER CHART 
 
 
  
LIST OF TABLES 
 
Sl. 
No TITLE Page No. 
1 Age and Sex distribution among study  population 51 
2 Duration of Immunosuppression favouring Fungal Infections 54 
3 Distribution and Categorisation of IFI among study  population 55 
4 Distribution of samples collected from  study  population with risk  factors 56 
5 Distribution of fungal  isolates in  clinical samples 58 
6 Distribution  of Candida  isolates and Filamentous fungal  isolates  causing IFI 60 
7 
A. Distribution of Candida  isolates causing IFI in clinical 
samples 62 
B. Distribution of Candida  isolates causing IFI in clinical 
samples 63 
8 Distribution of  Invasive Mycoses among Proven and Probable cases of IFI. 64 
9 Antifungal susceptibility testing in Candida species by Disk Diffusion method. 65 
10 Phenotypic characterisation - Phospholipase activity in Candida albicans 69 
11 Phenotypic characterisation - Phospholipase activity in Candida tropicalis 69 
12 Phenotypic characterisation - Phospholipase activity in Candida glabrata 70 
13 Phenotypic characterisation - Phospholipase activity in Candida parapsilosis 70 
 
  
  
Sl. 
No TITLE Page No. 
14 Phenotypic characterisation -Phospholipase activity in Candida krusei 71 
15 
A. Phenotypic characterisation - Hemolysin activity in 
Candida species 72 
B. Phenotypic characterisation -  Hemolysin activity in 
Candida species. 73 
16 Molecular analysis  - Identification of ERG 11 gene among Fluconazole resistance  Candida  species. 75 
17 Clinical  outcome of  the  study cases. 77 
 
  
LIST OF FIGURES 
 
Sl. 
No. TITLE 
Page 
No. 
1 
A. Sex   distribution among study  population 52 
B. Age  distribution among study  population 53 
2 Duration of Immunosuppression favouring Fungal Infections 54 
3 Distribution and Categorisation of IFI among study  population 55 
4 Distribution of samples collected from  study  population with risk  factors 57 
5 Distribution of fungal  isolates in  clinical samples 59 
6 Distribution  of Candida  isolates and Filamentous fungal  isolates  causing IFI 61 
7 Distribution of  Invasive Mycoses among Proven and Probable cases of IFI. 64 
8 
A. Antifungal susceptibility testing in Candida albicans by 
 Disk Diffusion method 66 
B.  Antifungal susceptibility testing in Candida tropicalis   
 by Disk Diffusion method 67 
C.  Antifungal susceptibility testing in Candida glabrata by 
 Disk Diffusion method 67 
D.  Antifungal  susceptibility testing in Candida   
 parapsilosis by Disk Diffusion method 68 
E. Antifungal susceptibility testing in Candida krusei  by 
 Disk Diffusion method 68 
9 
A.  Phenotypic characterisation - Hemolysin activity in 
 Candida species 72 
B. Phenotypic characterisation - Hemolysin activity in 
 Candida species 74 
10 Molecular analysis  - Identification of ERG 11 gene among Fluconazole resistance  Candida  species. 76 
11 Clinical outcome of the study cases. 77 
 
 
 
 
LIST OF COLOUR PLATES 
 
 
Sl. 
No. TITLE 
1 Identification of  Candida  albicans 
2 Identification of  Candida  tropicalis 
3 Identification of  Candida  glabrata 
4 Antifungal susceptibility testing by Disk diffusion method 
5 Phospholipase activity in Egg Yolk medium – Candida species 
6 Hemolysin activity in Blood Agar Plate - Candida species 
7 Aspergilllus  fumigatus 
8 Aspergilllus  flavus 
9 Aspergilllus niger 
10 Rhizopus 
11 Molecular  analysis  - Identification of ERG 11 gene among Fluconazole resistance  Candida  species. 
 
 
 
 
  
  
  
CERTIFICATE II 
 
 This is to  certify  that this  dissertation work  titled  “A STUDY   ON THE   
PATTERN OF FUNGAL INFECTIONS AND  CLINICAL PROFILE IN   
IMMUNOCOMPROMISED   PATIENTS  WITH SPECIAL   REFERENCE   TO 
CHARACTERISATION   AND MOLECULAR STUDY OF CANDIDA SPECIES 
IN A TERTIARY CARE HOSPITAL” of the  candidate Dr.M.AKILAMANI  
with registration number 201614001 for the award of M.D.,Degree  in the branch 
of Microbiology. I personally verified the urkund.com website for the purpose of 
plagiarism  check. I found that the uploaded thesis file contains from introduction 
to conclusion pages and result shows 2 percentage of plagiarism in the 
dissertation. 
 
 
 
 
 
 
Guide & Supervisor sign with seal  
 
 
 
 
 
Introduction 
  
1 
 
 
   
INTRODUCTION 
 
 In immunocompromised patients, there has been a steady increase in 
the frequency of opportunistic invasive fungal infetions (IFIs) 
(1)
. Invasive 
fungal infections caused by candida species and Aspergillus species are 
major causes of morbidity and mortality
(1)
. A definite increase in candida 
non-albicans species associated with a higher mortality has been reported
(2)
.  
 
 Aspergillus species are soil inhabitants. They cause life threatening 
disease, if Conidia are inhaled into the respiratory tract 
(3)
. Invasive 
Aspergillosis occurs in patients with risk factors like prolonged neutropenia 
, hematological malignancy and solid organ transplantation.
(3,5)
 
` 
 Over a 12 year period, the prevalence of invasive fungal infection is 
increased from 2.2% to 5.1% 
(4)
. Several reasons for the increase in invasive 
fungal infections are the use of antineoplastic and immunosuppressive 
agents, broad spectrum antibiotics, patients with uncontrolled Diabetes 
mellitus, neutropenia and more aggressive surgery 
(5)
. Some of the candida 
non-albicans are highly virulent and associated with treatment failure due to 
reduced susceptibility to antifungal agents
(5)
. 
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 The clinical manifestations of fungal infections are not specific 
(6)
.  
A high degree of suspicion is necessary for the early diagnosis and 
treatment of fungal infections 
(6)
. The gold standard for the diagnosis of 
invasive fungal infections (IFIs) is culturing the clinical specimen (sputum, 
urine, blood) to isolate the fungal agent 
(6)
. 
 
 Several new antifungals has expanded prophylaxis and treatment 
options for invasive fungal infections 
(7)
. The identification of candida 
species is important in the diagnostic laboratory
(8,9)
.  There is a prognostic 
and therapeutical significance, in the identification of candida species and 
thus early and correct antifungal therapy can be initiated. 
 
Hence this study was focussed to find the pattern of fungal infections 
and clinical presentation in immunocompromised patients and to identify 
the different fungal isolates. 
  
Aims &Objectives 
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AIMS & OBJECTIVES 
 
 To study the pattern of fungal infections and clinical profile in 
immunocompromised patients with special reference to characterisation 
and molecular study of candida species in a tertiary care hospital. 
 
 To isolate and identify the fungal etiology in immunocompromised 
patients. 
 
 To study the clinical profile of fungal infections in immunocompromised 
patients. 
 
 To study the antifungal susceptibility pattern of candida species by disk 
diffusion method. 
 
 To do the characterisation of candida species. 
 
 To perform molecular study of candida species. 
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
OVERVIEW: 
 In immunocompromised patients, there are advances in medical care 
leading to significant increase in invasive fungal infections (IFIs)
(10)
. Fungal 
species are approximately 7 percent (6,11,000 species) and they are 
distributed in soil, plant debris and other organic substrates 
(10)
. Only 600 
species are human pathogens 
(11)
. 
 
 Risk factors for invasive fungal infections include neutropenia (<500 
neutrophils / ml for >10 days) hematological malignancies, solid organ 
transplantation, chemotherapy, prolonged treatment (>4 weeks) with 
corticosteroids and prolonged stay (>7 days) in intensive care 
(12,13)
. Elderly 
patients with diabetes mellitus are also at risk
(2,14-18)
. Patients receiving 
chemotherapy, radiation therapy and immunosuppressants have weakened 
the immune system and thus develop opportunistic infections
(14,19)
. 
 
 Chemotherapy and radiotherapy can damage skin and mucosal 
surfaces which are anatomical barriers and thus allowing fungi to reach the 
tissue and blood 
(19)
.  
 
 A delay in establishing an early diagnosis remains a major problem to 
effective therapy 
(16,20)
. So, in invasive Aspergillosis and Candidiasis, 
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prompt initiation of antifungal therapy is critical for getting proper 
outcomes in patients
(16,20)
. Molecular detection methods with 
microbiological and clinical information have the potential to rapidly and 
accurately identify fungal pathogens
(21)
. It also indicates the response of the 
pathogen to conventional antifungal treatment 
(21)
. 
 
 The prevalence of IFIs ranges from 5% to 50% in kidney and liver 
transplants 
(22)
. In neutropenic patients, IFIs are the major cause of morbidity 
and mortality
(23)
. Candida non-albicans species are the most frequent cause 
of candidemia in ICU patients 
(30)
. 
 
 The fungi are eukaryotic, unicellular or multicellular organisms, with 
range of internal membrane system, membrane bound organelles and well-
defined cell wall, which is largely composed of polysaccharides and 
chitin
(24)
. 
 
The fungi are divided into 4 types, which are as follows:
(24)
 
(i) Yeasts – the yeasts are unicellular organisms and divide by 
budding. Cryptococcus species are pathogenic. 
 
(ii) Yeast-like – These fungi also reproduce by budding and exists as 
yeasts for a part of their life cycle but buds fails to get separated 
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hence elongation takes place forming pseudohyphae as seen in 
candida species. 
 
(iii) Molds – These fungi develop from spores, which germinate to 
form vegetative hyphae. The hyphae may or may not have 
septation. Dermatophytes, Aspergillus, penicillium, Rhizopus and 
mucor are a few examples of molds. 
 
(iv) Dimorphic fungi – These fungi have two types of morphology 
depending on different temperatures such as yeast form or 
spherule at body temperature i.e. 37
o
C and filamentous form at 
room temperature i.e. 25
o
C. The true pathogenic fungi are usually 
dimorphic and endemic in nature 
(24)
. 
 
 The fungi those reproduce sexually are classified under three phyla – 
glomeromycota, Ascomycota and basidiomycota 
(24)
. The anamorph fungi, 
which  lack known sexual state, have been placed in fourth major high-level 
taxon called deuteromycetes or fungi imperfecti or mitosporic fungi
(24)
. 
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CATEGORISATION OF INVASIVE FUNGAL INFECTIONS
(25-26)
 
 Revised standard definitions for the classification of invasive fungal 
infections is proven, probable and possible invasive fungal disease. Proven 
invasive disease can apply to any patient but the probable and possible 
category is for immunocompromised patients only. 
 
Criteria for proven invasive fungal disease except for endemic mycoses 
Analysis and Specimen Molds 
Microscopic analysis: 
sterile Material 
Histopathologic, cytopathologic, or direct 
microscopic examination of a specimen obtained by 
needle aspiration or biopsy in which hyphae or 
melanized yeast-like forms are seen accompanied by 
evidence of associated tissue damage 
Culture 
Sterile material 
Recovery of a mold or ―black yeast‖ by culture of a 
specimen obtained by a sterile procedure from a 
normally sterile and clinically or radiologically 
abnormal site consistent with an infectious disease 
process, excluding bronchoalveolar lavage fluid, a 
cranial sinus cavity specimen, and urine 
Blood 
Blood culture that yields a mold (e.g., Fusarium 
species) in the context of a compatible infectious 
disease process 
Serological analysis: CSF Not applicable 
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Criteria for proven invasive fungal disease except for endemic mycoses 
Analysis and Specimen Yeasts 
Microscopic analysis: 
sterile Material 
Histopathologic, cytopathologic, or direct 
microscopic examination of a specimen obtained by 
needle aspiration or biopsy from a normally sterile 
site (other than mucous membranes) showing yeast 
cells—for example, Cryptococcus species indicated 
by encapsulated budding yeasts or Candida species 
showing pseudohyphae or true hyphae 
Culture 
Sterile material 
Recovery of a yeast by culture of a sample obtained 
by a sterile procedure (including a freshly placed 
[<24 hr ago] drain) from a normally sterile site 
showing a clinical or radiological abnormality 
consistent with an infectious disease process 
Blood 
Blood culture that yields yeast (e.g., Cryptococcus 
or Candida species) or yeastlike fungi (e.g., 
Trichosporon species) 
Serological analysis: CSF 
Cryptococcal antigen in CSF indicates disseminated 
cryptococcosis 
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Criteria for probable invasive fungal disease except for endemic 
mycoses 
 
Host factors 
 Recent history of neutropenia (<0.5x109 neutrophils/L [<500 
neutrophils/mm
3
] for >10 days) temporally related to the onset of fungal 
disease Receipt of an allogeneic stem cell transplant. 
 Prolonged use of corticosteroids (excluding among patients with allergic 
bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/ 
day of prednisone equivalent for >3 weeks. 
 Treatment with other recognized T cell immunosuppressants, such as 
cyclosporine, TNF-α blockers, specific monoclonal antibodies (such as 
alemtuzumab), or nucleoside analogues during the past 90 days. 
 Inherited severe immunodeficiency (such as chronic granulomatous disease 
or severe combined immunodeficiency) 
Clinical criteria 
 Lower respiratory tract fungal disease 
The presence of 1 of the following 3 signs on CT: 
 Dense, well-circumscribed lesions(s) with or without a halo sign 
 Air-crescent sign  
 Cavity 
Tracheobronchitis 
 Tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar 
seen on bronchoscopic analysis 
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Sinonasal infection 
Imaging showing sinusitis plus at least 1 of the following 3 signs: 
 Acute localized pain (including pain radiating to the eye) 
 Nasal ulcer with black eschar  
 Extension from the paranasal sinus across bony barriers, including into the 
orbit 
CNS infection 
1 of the following 2 signs:  
 Focal lesions on imaging  
 Meningeal enhancement on MRI or CT 
Disseminated candidiasis 
At least 1 of the following 2 entities after an episode of candidemia within the 
previous 2 weeks: 
 Small, target-like abscesses (bull's-eye lesions) in liver or spleen  
 Progressive retinal exudates on ophthalmologic examination 
Mycological criteria 
Direct test (cytology, direct microscopy, or culture) 
 
Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate 
samples, indicated by 1 of the following: 
 Presence of fungal elements indicating a mold 
 Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, 
or Scedosporium species) 
 
Indirect tests (detection of antigen or cell-wall constituents) 
Aspergillosis 
 
11 
 
 
 
Galactomannan antigen detected in plasma, serum, bronchoalveolar lavage fluid, 
or CSF 
Invasive fungal disease other than cryptococcosis and zygomycoses  
β-D-glucan detected in serum 
 
 
Criteria for the diagnosis of endemic mycoses 
Proven endemic mycosis 
 
In a host with an illness consistent with an endemic mycosis, 1 of the following: 
 Recovery in culture from a specimen obtained from the affected site or 
from blood 
 Histopathologic or direct microscopic demonstration of appropriate 
morphologic forms with a truly distinctive appearance characteristic of 
dimorphic fungi, such as Coccidioides species spherules, Blastomyces 
dermatitidis thick-walled broad-based budding yeasts, Paracoccidioides 
brasiliensis multiple budding yeast cells, and, in the case of histoplasmosis, 
the presence of characteristic intracellular yeast forms in a phagocyte in a 
peripheral blood smear or in tissue macrophages 
 For coccidioidomycosis, demonstration of coccidioidal antibody in CSF, or 
a 2-dilution rise measured in 2 consecutive blood samples tested 
concurrently in the setting of an ongoing infectious disease process 
 For paracoccidioidomycosis, demonstration in 2 consecutive serum 
samples of a precipitin band to paracoccidioidin concurrently in the setting 
of an ongoing infectious disease process 
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Probable endemic mycosis 
 
 Presence of a host factor, including but not limited to those specified in 
table 2, plus a clinical picture consistent with endemic mycosis and 
mycological evidence, such as a positive Histoplasma antigen test result 
from urine, blood, or CSF 
 
 
EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS (27). 
 Candida species are the yeasts most commonly isolated from clinical 
specimens. Candida albicans is the most common cause of fungemia 
accounting for 50% and 60% of isolates. Species of candida other than 
C.albicans are also normal microbiota of cutaneous and mucocutaneous 
surfaces.non-candida albicans species were the causative agents in 46% of 
systemic infections has been reported. Candida tropicalis accounted for 
(25%), C.glabrata (8%), C.parapsilosis (7%) and C.krusei (4%). 
 
 Three categories to describe the involvement of lungs by Aspergillus 
species are (1) fungal ball (2) Allergic broncho pulmonary Aspergillosis (3) 
invasive Aspergillosis. Disseminated Aspergillosis, which most commonly 
occurs in severe immunosuppressed patients, often begins as invasive 
pulmonary Aspergillosis. Invasive pulmonary Aspergillosis occurs most 
exclusively in patients who are immunosuppressed or have neutropenia, 
particularly in those with leukemia or lymphomas. 
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 A fungal ball is a mass of hyphae from one or more molds that are 
growing in a saprophytic nature in a preexisting cavity. A.niger is the well 
recognized cause. A fungal ball caused by an Aspergillus species may be 
termed as Aspergilloma. The most common Aspergillus species causing 
allergic bronchopulmonary disease are A.flavus and A.fumigatus 
(27)
. 
 
 Infection caused by Fusarium spp and other hyaline septate 
monomorphic molds is becoming more common in immunocompromised 
patients 
(28)
. Acremonium species are also recognized as important 
pathogens in immunocompromised hosts. These have been associated with 
disseminated infection, fungemia, subcutaneous lesions and esophagitis
(28)
. 
Penicillium species are among the most common organism recovered by the 
clinical laboratory 
(28)
. Rhizopus is an important cause of morbidity and 
mortality in immunocompromised patients, particularly in patients with 
Diabetes mellitus
(28)
 
 
FUNGAL PATHOGENICITY 
(29)
 
 The ability of the fungi to cause mycoses are related to the 
immunological status of the host and exposure to the environment. Most of 
the fungi are unable to grow at 37
o
C. In the human body, thermotolerance is 
essential for fungal growth. 
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 Host defenses are specific and non-specific in nature. 
 
Specific defence mechanism: 
 Cell mediated immunity is regulated by T-lymphocytes. Humoral 
immunity is regulated by B-lymphocytes.  
 
Non specific defence mechanism: 
 Antifungal activity of natural excretions like saliva and sweat. 
 The protective effects of the normal microbiota of the skin and mucous 
membrane. 
 Mechanical barrier of skin and mucous membranes preventing entry of 
fungi. 
 The human body has non-specific inflammatory system. (neutrophils, 
mononuclear phagocytes, other granulocytes) to combat fungal 
proliferation. 
 
SPECIMEN COLLECTION AND PROCESSING 
(28)
 
 The diagnosis of fungal infections depends entirely on the selection 
and collection of an appropriate clinical specimen from microscopic 
analysis and culture. Proper collection of specimens and rapid transport to 
the clinical laboratory are crucial to the recovery of fungi. 
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FUNGI MOST COMMONLY RECOVERED FROM CLINICAL 
SPECIMENS 
(28)
 
Blood Pus and Exudates Respiratory secretions 
Candida spp 
Cryptococcus 
neoformans 
Aspergillus spp 
Cryptococcus 
neoformans 
Dimorphic fungi Candida spp 
Histoplasma 
capsulatum 
Fusarium spp 
Cryptococcus 
neoformans 
Dimorphic fungi 
Mucor spp 
Rhizopus spp 
 
Cerebrospinal fluid Urine 
Cryptococcus neoformans Candida spp 
Candida spp Cryptococcus spp 
Coccidiodes immitis  
Histoplasma capsulatum  
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SIGNS AND SYMPTOMS 
 Symptoms of invasive fungal infections are non-specific in the early 
stages of the disease. Initially, pulmonary Aspergillosis may cause cough, 
pleural pain or hemoptysis. In mould infection, during prolonged 
granulocytopenia, sinusitis with local necrotic lesion may occur. Dysphagia 
and retrosternal burning may occur in fungal esophagitis. These symptoms 
may also occur following high-dose cytarabine or Herpes viral ulcers
(31)
. 
 
 Skin infiltrations during pancytopenia may be due to yeast and mould 
infections and other pathogens. These skin infiltration may be 
misinterpreted as thrombopenic purpura 
(32)
. Hepatospelnic candidiasis 
cause persistent fever, hepatosplenomegaly increased alkaline phosphatase 
and fungal endophthalmitis cause posterior uveitis, showing cotton 
woolspots develop after neutrophil recovery. 
 
 In systemic candida infections, brain, heart, kidney and bone may be 
affected by hematogenous spread. In hematological malignancies 
Aspergillus sp. may cause invasive fungal disease (IFD) involving central 
nervous system 
(33)
. 
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Categories of evidence used in these guidelines modified according to 
(76)
 
Category, Grade Definition 
Strength of 
recommendation 
 
A Good evidence to support recommendation for use 
B Moderate evidence to support recommendation for use 
C Poor evidence to support recommendation 
D 
Moderate evidence to support recommendation against 
use 
E Good evidence to support recommendation against use 
 
KEY RECOMMENDATIONS OF THE AGIHO FOR DIAGNOSIS OF IFD 
IN PATIENTS WITH CANCER
(76)
 
Recommendations Strength 
General recommendations  
The highest level of evidence for the presence of IFI should be 
obtained before initiating systemic antifungal therapy 
A 
Most signs and symptoms related to IFI are unspecific and require 
further diagnostic procedures 
A 
A combination of various methods with regular screenings is 
mandatory for early diagnosis of IFD, as well as for monitoring 
response to antifungal treatment 
A 
Microscopy A 
Tissue samples from patients with suspected IFD should be examined 
not only by mycological culture but also by microscopy 
A 
Bronchoscopic material or tissue biopsies should be examined with 
periodic acid–Schiff, Grocott‘s methenamine silver or optical 
brighteners 
A 
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Mycological culture A 
All clinical samples from patients at high risk for IFD must be 
cultured for fungi 
A 
All fungi recovered from sterile sites should be identified down to the 
species level 
A 
Yeasts, if found in sputum or bronchoalveolar lavage (BAL) fluid, 
should be regarded as contamination or colonization until invasive 
disease is proven 
A 
Recovery of moulds from sputum in patients with clinical signs 
suggestive for IFD and prolonged granulocytopenia should be 
regarded as a possible indicator of fungal pneumonia 
B 
Any fungi cultured from urine of a severely granulocytopenic patient 
without a urinary catheter may be interpreted as an indication of 
fungal infection 
B 
Any fungi cultured from urine of a severely granulocytopenic patient 
without a urinary catheter may be interpreted as an indication of 
fungal infection 
B 
Antigen and antibody detection  
Cerebrospinal fluid should be cultured with simultaneous antigen 
testing for Cryptococcus neoformans 
A 
Routine Candida antibody and antigen testing is not recommended 
for patients with haemato-oncological malignancies 
E 
Routine antigen detection with the Aspergillus galactomannan 
ELISA test is considered advisable (twice weekly or more frequently) 
A 
Routine testing for Aspergillus antibodies is not recommended E 
Screening of BG in plasma for the diagnosis of IFI may be 
recommended in high-risk hematological patients 
B 
Molecular diagnostics  
Molecular diagnostic tools (e.g. Aspergillus PCR) are promising and 
display high sensitivity and specificity 
A 
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Studies suggest that molecular diagnostic methods should be used in 
combination with other non-cultural tests such as antigen detection 
B 
Since fungal PCR is neither a standardized nor a widely available 
diagnostic tool, it is not yet included as mandatory in the 
recommendations 
B 
Imaging procedures  
In patients with granulocytopenia, HRCT should be preferred to chest 
X-rays for primary diagnosis in high-risk patients 
A 
The ‗halo sign‘ is highly suggestive, even not specific, as an early 
sign for invasive pulmonary mould infection in granulocytopenic 
patients 
B 
Fungal infections in the liver and/or spleen can be best visualized by 
CT and particularly by MRI scanning 
B 
Fungal infections in the gastrointestinal tract can be best visualized 
by CT and particularly by MRI scanning 
B 
MRI should be preferred over CT for imaging studies in fungal 
diseases of CNS, sinus and eyes 
A 
Endoscopic methods  
Bronchoscopy with BAL may be useful for work-up of pulmonary 
infiltrates 
B 
Oesophagogastroduodenoscopy (preferably with biopsy) should be 
carried out in patients with signs and symptoms of esophagitis not 
responding to (preemptive) antifungal therapy 
A 
Organ biopsy  
If clinically feasible, biopsy specimens should be taken from 
suspected areas (skin, organ lesions) 
A 
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ANTIFUNGAL SUSCEPTIBILITY TESTING 
(24)
 
 The antifungal susceptibility testing is performed to provide 
information to select an appropriate drug suitable for treating a particular 
fungal infection. The changing epidemiology of fungal agents, increasing 
drug resistance, availability of more and newer antifungals, increasing 
practice of prophylactic use have made it necessary to go for AFST for 
isolates obtained from clinical material. 
 
The focus of intensive research for the past 15 years is development 
of standardized antifungal susceptibility testing methods.
(34)
 
 
Some of the antifungal susceptibility testing methods are: 
(24)
 
1) Broth dilution method 
2) Disk diffusion method 
3) E test  
4) Neo-sensitabs 
5) Colorimetric methods 
6) Spectrophotometric methods 
7) Flow cytometry 
8) VITEK 2 yeast susceptiblity test 
9) Bioluminescence Assay 
10) Ergosterol Quantitation method 
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1) Broth dilution method 
 Yeast : The CLSI M27 document was proposed in 1992 after two 
multi-cenric studies which provided data on critical facts affecting 
reproductibility of testing from one laboratory to another, are as follows 
 End point definition 
 Inoculum preparation and size 
 Incubation time 
 Temperature 
 Media  
 
 Presently used approved version of CLSI document (M27-A3) on 
standard broth dilution and microdilution methods for antifungal 
susceptibility testing of yeasts was originally released in April, 2008. 
 
Mycelial fungi 
 The CLSI had also proposed antifungal susceptibility testing of 
Conidia forming filamentous fungi in 1998, which can be now be performed 
as per M38-A2 document on a similar pattern as that of yeast.  
 
2) Disk Diffusion Method 
 In this method, disks containing antifungal agents diffuses in the 
surrounding medium, inhibiting growth of fungi and measurements of zone 
of inhibition are taken, accordingly. The CLSI reference document for 
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performing this method is M44-A 
(24)
. It was used for determination of 
susceptibility of candida species to fluconazole 
(35)
. For fluconazole, there 
was a good correlation with the reference broth methods 
(35-37)
. 
 
 Zone edge definition can be improved by adding methylene blue 
(0.5g/ml) to the surface of the plate which facilitates reading (38). The 
susceptibility of candida species to fluconazole correlates with clinical 
outcome of candidiasis 
(39)
. 
 
3) E-test (Epsilometer test) 
 It is a commercial method for determination of MIC. 
 
4) Neo-sensitabs 
 In this method, both modified RPMI-1640 agar supplemented with 
0.2% glucose and Mueller-Hinton agar with 2% glucose and 0.5g/ml 
methylene blue, have been used. 
 
5) Colorimeter methods 
 This is an alternative to the CLSI reference procedures in which 
growth of isolates is measured in cultures containing just one or two 
antimicrobial drug concentrations that distinguish resistant from susceptible 
strains.  
 
23 
 
 
 Fungitest – It is a commercial micro-plate panel for break point 
testing of yeasts like candida and Cryptococcus species against various 
antifungals. 
 
 Yeast one sensitive Assay – A commercial system that includes a 
colorimetric response is marked at sensitive yeast one antifungal panel. it is 
based on broth microdilution methodology. 
 
6) Spectrophotometric methods 
 MIC end points are more objectively determined by reading both 
microdilution plates with spectrophotometer. 
 
7) Flow Cytometry 
 This method allows the detection of antifungal resistance and 
estimates the impact of the molecule tested on the viability and cell damage 
of the tested fungus. 
 
8) Vitek 2 yeast susceptibility test 
 Antifungal susceptibility testing for yeasts can be performed by 
automated methods such as VITEK 2. 
 
9) Bioluminescence Assay 
 It is based on the capacity to measure adenosine triphosphate (ATP) 
produced by fungi. 
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10) Ergosterol Quantitation Method 
 The method is based on measurement of cellular ergosterol content 
rather than growth inhibition i.e. Sterol Quantitation Method (SQM). 
 
ANTIFUNGAL THERAPY 
(24)
 
 The treatment of fungal infections in immunocompromised patients is 
really a challenging task .only a few antifungal agents are effective and safe 
to use. Most of these drugs are fungistatic except a few like Amphotericin 
B, allylamine, benzylamine and morpholines, which are fungicidal in nature. 
Therefore keeping in view of increasing resistance and tolerability of drug 
in special circumstances like renal failure, lipid formulation and azoles are 
two main stays for antifungal therapy. 
 
 Studies have shown synergism between many antifungal agents. So, 
combining antifungals in the treatment of invasive fungal infection is 
recommended. 
(40)
 
 
Clinically important antifungals 
* Polyene antibiotics   - Amphotericin B  
     - Nystatin 
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* Synthetic antifungals  
 Azoles – Triazoles  -  Fluconazole 
      Voriconazole 
      Itraconazole 
* Miscellaneous  
 Antifungal    -  Flucytosine 
     - Echinocandins 
 
Amphotericin B 
 It is divided into two broad groups (1) conventional Amphotericin B 
(2) Lipid-based formulations of Amphotericin B. 
 
1) Conventional Amphotericin B 
 The conventional drug (Fungizone) powder for injection, is supplied 
in vials of 50mg (50,000 IU) as deoxycholate amphotericin B. It is given 
through i.v. infusions in 5% dextrose over 2-4 hours. Intrathecal injections 
may also be given in fungal meningitis caused by coccidioides species. It 
may be used for bladder irrigation in candiduria cases. Inhalational therapy 
by nebulization may be used in pulmonary Aspergillosis. 
 
 The daily dose is 0.6mg/kg of body weight (range 0.25 – 1.0 mg/kg) 
and is increased to level of 40-50mg/day and the total dose of entire 
antifungal course should not exceed 2 to 2½ gm. Amphotericin B cause 
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significant renal and infusion – related toxicities, which limits its therapeutic 
uses. 
 
2) Lipid – based formulations of Amphotericin B 
 It can be easily given in higher dosage of 3-5 mg/kg body weight. 
These preparations have potential efficacy in the treatment of systemic 
fungal infections due to their lesser toxicity to mammalian cells as 
compared to conventional amphotericin B. 
 
The following three lipid based preparations are approved for clinical use. 
(i) Amphotericin B lipid complex 
(ii) Amphotericin B colloidal dispersion 
(iii) Liposomal – encapsulated amphotericin B 
 
Nystatin 
 It exhibits fungistatic and fungicidal activity depending on its drug 
concentration, susceptibility of fungus, presence of blood, pus or tissue 
fluid, which reduces its activity. It is not absorbed after oral intake hence 
therapeutic use is limited to topical form in oral cavity and gastrointestinal 
tract. It is essentially insoluble in water and alcohol and is used topically for 
cutaneous, mucocutaneous infections, particularly caused by candida 
species. 
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Fluconazole 
It is effective in yeast – like fungi e.g. vaginal, oropharyngeal, 
esophageal and systemic candidiasis after oral administration. In culture 
proven, acute Cryptococcal meningitis, fluconazole is effective in dose of 
100-200mg/day even in AIDS patients. In histoplasmosis, blastomycosis, 
coccidioidomycosis and Aspergillosis, the drug has shown mixed response 
after 1-2 months. 
 
 The drug resistance to fluconazole has been reported particularly in 
candida species and it is not effective in c.krusei and c.glabrata. 
Indiscriminate use of fluconazole, particularly as prophylactic agent in 
routine clinical practice, may be responsible for high drug resistance. 
          
Molecular mechanisms of fluconazole resistance in Candida spp
(72)
 
Mechanism Gene involved Species 
Drug target 
overexpression 
ERG11 
Candida albicans,Candida 
parapsilosis,Candida 
tropicalis 
Drug target alteration ERG11 
Candida albicans,Candida 
parapsilosis,Candida 
tropicalis,Candida auris 
Aneuploidy/ loss of 
heterozygosity 
ERG11 Candida albicans 
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Itraconazole 
 It is a broad spectrum antifungal agent, active against most of the 
pathogenic yeast as well as mycelial fungi except mucormycetes. It is very 
effective in superficial mycoses like dermatophytoses, oral and vaginal 
candidiasis, pityriasis vesicolor and and keratomycosis. It has also shown 
good response in systemic infections like disseminated Aspergillosis, 
Cryptococcosis, Sporotrichosis, Histoplasmosis, Blastomycosis, 
Coccidioidomycosis, Paracoccidioidomycosis, Phaeohyphomycosis 
Eumycetoma and Chromoblastomycosis caused by Cladosporium species. 
 
 It is available as 100mg capsules and daily oral dose is 100 to 400mg. 
 
Voriconazole 
 It has potent antifungal activity against various fungi including those 
which are inherently supposed to be resistant to fluconazole, like non-
albicans Candida species, C.krusei. The strength of voriconazole lies in its 
strong activity against Aspergillus and Cryptococcus, its broad spectrum 
activity against Candida species and low toxicity and good bioavailability.  
 
Flucytosine 
 It is a narrow spectrum antifungal drug and is particularly used for 
treatment of Cryptococcosis and Chromoblastomycosis. The daily oral dose 
of Flucytosine is 150mg/kg six hourly. It can also serve as a companion 
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drug to Amphotericin B and in combination, it is having synerigistic effect 
against most isolates of Cryptococcus and Candida species. 
 
Echinocandins 
 These have efficient activity against Candida and Aspergillus species 
however moderately against Histoplasma, Blastomyces and Scedosporium 
species. All these are available as intravenous preparations. 
 
Antifungals combination therapy 
 For initial and salvage treatment of invasive Aspergillosis, when 
voriconazole cannot be administered IDSA practice guidelines suggested 
use of Amphotericin B and its lipid derivative 
 For invasive Aspergillosis, Echinocandins are listed in these guidelines 
as effective in salvage therapy either alone or in cominbation 
(41)
. 
 In patients with candida native valve endocarditis, candida CNS 
infection, azole-resistant candida glabrata, ascending pyelonephritis and 
fluconazole resistant candida endophthalmtis, IDSA recommends use of 
Amphotericin B with or without flucytosine for initial combination 
antifungal (CAF) therapy
(42)
. 
 European society of clinical microbiology and infections disease and 
European confederation of medical mycology joint clinical guidelines 
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recommend surgical rebridement and Amphotericin B or its lipid 
derivative for management of Mucormycosis 
(43)
. 
 
Suggested mechanisms of synergism and Antagonism
(44-49, 50-52)
. 
Combination 
of 
antifungals 
Synergism 
(S) or 
antagonism 
(A) 
Mechanism Reference 
Terbinafine + 
azole 
S 
Inhibition of 
ergosterol 
biosynthesis 
Barchiesi et al  
(C. albicans) Guerra et al  
(C. neoformans) Ashley 
and Johnson 
(Dermatophytes)  
Perea et al  (C. glabrata) 
AmB or azole 
+ flucytosine 
S 
Cell wall damage 
(AmB or azole) 
and increase 
uptake of 
flucytosine 
Yamamoto et al  
(pulmonary 
cryptococcosis) Polak 
(septicemic candidiasis) 
AmB + azole A 
Modification of a 
target in the 
fungal cell 
(prevention of 
ergosterol 
synthesis by the 
azole) 
Sugar and Liu (invasive 
candidiasis)  
Baddley et al (invasive 
candidiasis) 
AmB + 
flucytosine 
A 
Changing of the 
cell membrane 
function 
Shadomy et al (C. 
neoformans and C. 
tropicalis) 
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Commonly Used CAF Therapy 
(41-43, 53-55, 56-57).
 
Commonly used CAF therapy 
Invasive candidiasis 
AmB + flucytosine 
AmB + azole 
Echinocandin + azole 
Pappas et al , 2016 IDSA 
guidelines 
Rex et al 
Cui et al 
Chen et al 
Invasive 
aspergillosis 
Azole or AmB + 
echinocandin 
Voriconazole + 
anidulafungin 
Patterson et al , 2016 IDSA 
guidelines  
Panackal et al 
Marr et al 
Mucormycosis 
AmB + posaconazole 
or caspofungin 
Cornely et al 
 
  
Materials & Methods 
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MATERIALS AND METHODS 
 
STUDY PLACE 
 This cross sectional study was conducted in the Institute of 
Microbiology in association with Department of Hematology, Department 
of Medical Oncology and Institute of Internal Medicine, Madras Medical 
College and Rajiv Gandhi Govt. General Hospital, Chennai – 3. 
 
STUDY PERIOD 
 The study was undertaken for a period of one year from March 2017 
to February 2018. 
 
ETHICAL CONSIDERATIONS 
 Approval for the study was obtained from the Institutional Ethical 
Committee, Madras Medical College and Rajiv Gandhi Government 
General Hospital, Chennai – 3 before commencing it. Informed consent was 
obtained from the study population. All patients satisfying the inclusion 
criteria were documented. Patients were interviewed by structured 
questionnaire. 
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STUDY POPULATION  
INCLUSION CRITERIA 
1. Patients aged more than 18 years. 
2. Immunocompromised patients included in the study are patients with 
acute hematological malignancy with intensive chemotherapy, cancer 
patients, complicated intensive care unit patients and patients on long 
term steroids and antibiotic therapy. 
 
EXCLUSION CRITERIA 
1. Age of patients below 18 years. 
2. Patients on antifungal therapy. 
 
DATA COLLECTION 
 Data collection included Name, Age, Sex, IP number, Ward, 
Occupation, Address, Date of admission, Diagnosis at admission, presenting 
complaints, personal history, past history, H/o. Diabetes mellitus, chronic 
kidney disease, neoplasm, immunosuppressive therapy, previosu IFI, prior 
antibiotic therapy / antifungal therapy. 
 
CASE DEFINITIONS 
(25)
 
 Invasive fungal infections are defined in terms of proven IFD, 
probable IFD and possible IFD. 
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PROVEN IFD 
Molds 
 Histopathologic, cytopathologic, or direct microscopic examination of 
a specimen obtained by needle aspiration or biopsy. 
 Positive culture obtained by sterile procedure from a normally sterile 
site and clinically and radiologically abnormal site consistent with an 
infectious disease process excluding bronchoalveolar lavage fluid,a 
cranial sinus cavity specimen and urine. 
 Blood culture yields a mold (e.g., Fusarium species) accompanied 
with a compatible infectious disease process 
 
Yeasts 
 Histopathologic, cytopathologic, or direct microscopic examination of 
a specimen obtained by needle aspiration or biopsy excluding mucous 
membrane. 
 Positive culture obtained by a sterile procedure from a normally 
sterile and clinically or radiologically abnormal site consistent with an 
infectious disease process. 
 Positive blood culture of Candida spp, Cryptococcus spp, 
Trichosporon spp. 
 Antigen positivity for Cryptococcus spp in CSF  
35 
 
 
 
PROBABLE IFD  
 It requires the presence of a host factor, a clinical criterion and a 
mycological criterion. 
 
POSSIBLE IFD 
 Cases that meet the criteria for a host factor and a clinical criterion 
but for which mycological criteria are absent are considered as possible 
IFD.  
 
SPECIMEN COLLECTION FOR FUNGAL CULTURE
(27)
 
 Sputum-The first early morning sample was collected after vigorous 
rinsing of mouth with water. Sputum was coughed out following a 
deep breath, collected into a sterile, screw capped container. 
 Bronchoscopy- bronchial brushing, bronchoalveolar lavage fluid was 
collected and transported in sterile sealed container. 
 Cerebrospinal fluid – as much CSF as possible collected aseptically 
transported in sterile sealed container and processed without delay. If 
delayed, sample left at room temperature. 
 Urine- The first early morning clean catch mid stream urine specimen 
was collected aseptically in sterile, screw capped container and 
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processed immediately. If delay more than 2 hours is anticipated, 
sample should be refrigerated at 4 . 
 Exudates- After using disinfectant, exudates from deep abscess site 
aspirated using sterile needle and syringe. 
 Blood- After disinfecting the venipuncture site with 70% alcohol, 
blood samples were collected at the febrile episode in a sterile culture 
broth. 
 
CRITERIA FOR SPECIMEN REJECTION
(27)
 
 Unlabelled samples 
 Sputum specimen with > 25 squamous epithelial cells per low –power 
field (criteria for rejection of respiratory samples submitted for 
bacterial culture) 
 Samples collected in insufficient volume 
 Samples received in unsterile container 
 Samples that have leakage or show evidence of drying 
 
PROCESSING OF SPECIMENS 
(27)
 
 Respiratory specimen- Most purulent or blood flecked parts of the 
sample are selected for culture. Highly viscid sample was 
homogenized by adding a pinch of crystalline N-acetyl-L-
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Cystine.Since respiratory secretions are contaminated with bacteria, 
media containing antibiotics are used for primary isolation. 
 Cerebrospinal fluid(CSF)- CSF samples centrifuged at 1500-2000 g 
for 20 min and inoculated on non inhibitory  culture media. 
 Urine- About 10 ml of urine sample centrifuged , then 0.5 ml of 
sediment was inoculated on both inhibitory and non inhibitory agar 
medium. 
 Blood- 5-10 ml of blood sample inoculated in brain heart infusion 
broth. 
 
MICROSCOPY 
(24)
 
1) KOH Wet Mount 
 On a clean, grease free glass slide, drop of KOH (10%) was placed 
and a small quantity of specimen was mixed with it. A sterile coverslip was 
placed over the drop. The aqueous potassium hydroxide (KOH) softens and 
digests protein debris as well as dissolves cement substance, which holds 
keratinized cells together. The fungal elements become quite clear and easy 
to visualize in clinical specimens observed under low and high power of the 
light microscope for the presence of yeast or hyphal forms. 
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2) Gram Stain  
 For Gram staining, fix smear by passing it over flame. Place 0.5% 
aqueous crystal violet solution on slide for 20 seconds, wash again with tap 
water. Apply Gram‘s iodine solution over slide for 20 seconds. Wash again 
with tap water. Decolorize quickly with solution of equal parts of acetone 
and 95% ethanol and wash immediately in running tap water. Counter stain 
with 0.5% aqueous safranin for 10 seconds. Again wash with tap water, air 
or blot dry and examined under microscope. Fungal elements or yeast forms 
were observed. 
 
3) India Ink Stain 
 This is one of the negative staining techniques used for visualizing 
encapsulated microorganisms like Cryptococcus species. A drop of clinical 
specimen, such as CSF is mixed with an equal amount of India ink on the 
glass slide. A sterile cover slip was placed over it. Mount examined 
microscopically for the presence of encapsulated, budding yeast cell. 
 
CULTURE 
(24)
 
A minimum amount of specimens was inoculated onto 2 slants of 
sabouraud dextrose agar of pH 5.6 with antibiotic Gentamicin at 50mg/liter 
inoculated tubes are incubated for a period of 4-6weeks before discarding 
the tubes as sterile and negative. 
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Interpretation of fungal culture 
 The significance of fungal isolate depends on its source and identity. 
The following points should be considered in case of commensal or 
opportunistic fungi that are otherwise considered as contaminants. 
 
o Growth of same strain in all culture tubes. 
o Repeated isolation of same strain in multiple specimens. 
o Immune status of patients and  
o Serological evidence to confirm significance of isolate. 
 
Identification of fungal isolates 
All fungal isolates were systematically identified by standard techniques: 
 Yeast – The biochemical rather than morphological criteria were used 
for identification of yeast. Important biochemical reaction are ability to 
assimilate certain carbon and nitrogen compounds, ferment sugars, germ 
tube test. Special media like CHROM agar were also performed to 
differentiate the species. 
 
 Molds – These fungi develop from spores, which germinate to form 
vegetative hyphae. The hyphae may or may not have septation. The 
lactophenol cotton blue mount is the best method used to study 
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morphological features of fungal isolates after the strain is grown on culture 
medium. 
 
CHROM agar candida medium 
 The CHROM agar candida is selective and differential type of 
chromogenic medium, which was used for identification of various candida 
species. Due to chromogenic substrate in the medium, the colony 
morphology and color have been well defined when it was used to isolate 
the yeast directly from the clinical specimen. 
 
 The CHROM agar medium can be used for simultaneous isolation as 
well as presumptive identification of various candida species like 
C.albicans, C.krusei, C.tropicalis, C.glabrata, C.parapsilosis, C.dubliniensis. 
 
The benefits of using this medium are that it shortens time for 
presumptive identification of organisms and it also allows for easier 
detection of multiple yeast species present in the clinical specimen with 
mixed infection. The CHROM agar candida shows the following colors of 
colonies after incubation at 30
o
C for a period of 48-72 hrs. 
 C.albicans – light green 
 C.dubliniensis – dark green 
 C.glabrata – pink to purple 
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 C.krusei - pink 
 C.parapsilosis – cream to pale pink 
 C.tropicalis – blue with pink halo 
 
MOLDS 
OBSERVATION 
 Macroscopic morphology on SDA – obverse and reverse was observed 
and noted. 
 Microscopy – LPCB mount 
For preparing LPCB mount, take out a small fragment of fungal culture 
on a glass slide with L-shaped loop. Add a drop of LPCB stain and tease 
the culture properly with the help of two teasing needles.  Coverslip was 
placed and examined under the microscope. Characteristic fungal 
morphology was observed.  
 
Biochemical reaction
(24)
 
 Carbohydrate Assimilation Test 
 Germ Tube Test 
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Carbohydrate Assimilation Test 
 Based on the utilization of different carbohydrates Candida species 
can be identified. 3 generation of the test organism is done on nutrient agar 
slope.  
 1st day : subculture onto 1 NA slope and incubate at 37oC for 24 hrs – 1st 
generation. 
 2nd Day : Subculture from 1st generation onto 1 NA slope and incubate at 
37
o
C for 24 hrs. 
 3rd generation : Add 2ml saline to 3rd generation slopes, washed and  
suspension was made .  
 
 Transferred 2ml of yeast suspension into another sterile tube 
containing 1.5ml of YNB (Yest nitrogen base). Added this into 13.5 ml of 
molten and cooled (40-45
o
C) plain agar. Twirled and poured into sterile 
petri dish which was prelabelled, with 20% sugars (glucose, sucrose, 
maltose, lactose, galactose, xylose, cellobiose, mellibiose, raffinose, 
rhamnose, dulcitol, inositol, trehalose). Allowed it to solidify. Placed 
individual sugars with the help of whatman filterpaper (6mm) in the 
appropriate marked area by using 2mm diameter loop. Incubated at room 
temperature (25
o
C). 
Interpretation : Growth around the disc was taken as assimilation of sugar 
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Assimilation reactions of different candida species 
Candida species Glu Mal Suc Lac Cel Gal Tre Raff Mel Xyl Ino Dul 
Candida 
albicans 
+ + + + + + + - - + - - 
C.tropicalis + + + - + + + - - + - - 
C.kefyer + - + + + + - + - + - - 
C.parapsilosis + + + - - + + - - + - - 
C.guilliermondii + + + - + + + + + + - + 
C.krusei + - - - - - - - - + - - 
C.glabrata + - - - - - + - - + - + 
 
Note : Glu = Glucose, Mal = Maltose, Suc = Sucrose, Lac = Lactose, Cel = 
Cellobiose, Gal = Galactose, Tre = Trehalose, Raf = Raffinose, Mel = Melibiose, 
Xyl = Xylose, Ino = Inositol, Dul = Dulcitol; + = Positive Reaction, - = Negative 
Reaction, V = Variation. 
 
Germ Tube Test 
 The observation of Germ tube production is a quick method for 
presumptive identification of C.albicans isolates from clinical samples. This 
is also known as Reynolds – Braude Phenomenon. 
 
The culture of candida species was treated with 0.5ml mammalian 
serum from fetal bovine, horse, sheep or normal human being and incubated 
at 37
o
C for 2-4 hrs and a drop of suspension was examined under low and 
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high power objectives. The formation of tube like protrusion from the 
mother  cell was considered as germ tube production. 
 
A drop of suspension was taken on the slide and examined under the 
microscope. The germ tubes are seen as long tube – like projections 
extending from the yeast cells. They grow at distal end. There is no 
constriction at the point of attachment to yeast cell. The germ tubes are 
formed within two hours of incubation in C.albicans and C.dubliniensis. 
 
ANTIFUNGAL SUSCEPTIBILITY TESTING OF CANDIDA 
Disk Diffusion Method  
 Inoculum was prepared by picking 5 distinct colonies and suspending 
them in 5 mL of sterile normal saline. Vortex the suspension for 15 seconds 
to prepare a uniform inoculum. Adjust the turbidity with a 
spectrophotometer set at 530 nm or Mc Farlands standard to achieve a stock 
of 1-5 x 10
6
 cells/mL. Within 15 minutes of preparation, a sterile cotton 
swab dipped into the suspension and the excess suspension squeeze out on 
the side of the tube is taken and streaked onto the Mueller Hinton Media 
rotating the plate at an angle of 60
o
 thrice. 
 
 The antifungal disk is placed onto the surface to ensure complete 
contact with the agar with the aid of an inoculators. This is done within 10-
15 minutes of plating the test organism. 
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 No more than 5 disks must be placed on a 90-100 mm petriplate. 
Incubate the plates in a 35
o
C  incubator (+ 2
o
C) for 24 hours. 
 
 The plates are read with reflected light. Clear zones of inhibition are 
measured in millimeters (mm). Pinpoint and microcolonies are ignored at 
the zone edge and within the zone of inhibition for these drugs tested. Zone 
of inhibition is interpreted based on the CLSI breakpoints as susceptible, 
intermediate susceptible or susceptible dose dependent. 
 
PHENOTYPIC METHODS  
 Phospholipase activity 
 Hemolysin activity 
 
PHOSPHOLIPASE ACTIVITY
(58)
 
 All Candida species isolated were tested for production of 
phospholipase activity. The test was performed by growing them on egg 
yolk agar and measuring the size of zone of precipitation. The egg yolk 
medium consisted of 65g SDA, 58.4g NaCl and 5.5 g CaCl2 dissolved in 
980ml distilled water and sterilized at 1210c for 15 minutes.Egg yolk was 
centrifuged at 5000 g for 30 minutes and 2 ml of supernatant was added to 
medium cooled at 45-50 .An aliquot of 10µl yeast suspension was spot 
inoculated on egg yolk agar medium and incubated at 37  for 4 days. The 
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diameter of precipitation zone was determined.Phospholipase activity was 
calculated by applying following equation: 
 
 Pz vaiue= Colony diameter /  Colony diameter + Zone of 
precipitation 
 
On the basis of  Pz value, Phospholipase activity was classified into 5 types, 
Pz value=1 (test strain is negative for Phospholipase ) 
Pz value < 0.90-0.99= weak Phospholipase activity(+) 
Pz value 0.80-0.89= Poor Phospholipase activity(++) 
Pz value 0.70-0.79= Moderate Phospholipase activity(+++) 
Pz value <0.70 = Intense Phospholipase activity(++++) 
 
HEMOLYSIN ACTIVITY 
(59)
 
 All the Candida isolates were tested for hemolysin production. A 
suspension of each candida isolate was prepared in phosphate buffer 
solution (PBS) and turbidity was adjusted to 0.5 Mcfarland standard (10
6
 
cells/ml). Then 10 µl of the candida suspension was spot inoculated on a 
sugar –enriched sheep blood agar medium.Then the media was incubated at 
37  in 5% Co2 for two days.  
 Greenish black ring around each colony-Incomplete(alpha hemolysis) 
 Ring of lysis-Complete (Beta hemolysis) 
 Lack of greenish black ring-no hemolysin activity(Gamma hemolysis) 
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MOLECULAR METHODS 
(72)
 
 Molecular study of candida species is done by polymerase chain reaction 
(PCR).  
 Fluconazole resistance candida species was determined by antifungal 
susceptibility testing by disk diffusion method. 
 Identification of ERG11 gene was done in fluconazole resistance candida 
species. 
 
Candida DNA Purification 
1. 1ml of culture centrifuged at 6000rpm for 5min 
2. Supernatant discarded 
3. Pellet is suspended in 0.2ml PBS. 
4. 180μl of Lysozyme digestion buffer and 20μl of Lysozyme [10mg/ml] 
added. 
5. Incubated at 37C for 15min. 
6. 400μl of Binding buffer, 5μl of internal control template and 20μl of 
Proteinase K added, Mixed well by inverting several times. 
7. Incubate at 56ºC for 15min. 
8. Added 300μl of Ethanol and mixed well. 
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9. Transferred entire sample into the PureFast® spin column. Centrifuged 
for 1 min. Discard the flow-through and place the column back into the 
same collection tube. 
10. Added 500μl Wash buffer-1 to the PureFast® spin column. Centrifuge 
for 30-60 seconds and discard the flow-through. Place the column back 
into the same collection tube. 
11. Added 500μl Wash buffer-2 to the PureFast® spin column. Centrifuge 
for 30-60 seconds and discard the flow-through. Place the column back 
into the same collection tube. 
12. Discard the flow-through and centrifuge for an additional 1 min. This 
step is essential to avoid residual ethanol. 
13. Transferred the PureFast® spin column into a fresh 1.5 ml micro-
centrifuge tube. 
14. Added 100μl of Elution Buffer to the center of PureFast® spin column 
membrane. 
15. Incubate for 1 min at room temperature and centrifuge for 2 min. 
16. Discard the column and store the purified DNA at -20°C. Quality and 
Quantity of extracted DNA is checked by loading in 1% agarose gel 
and 5μl of extracted DNA is used for PCR amplification. 
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PCR Procedure: 
1. Reactions set up as follows; 
Components Quantity 
HELINI RedDye PCR Master mix 10 l 
HELINI Ready to use - Primer Mix 5 l 
Purified Purified DNA 5 l 
Total volume 20 l 
 
2. Mixed gently and spin down briefly. 
3. Place into PCR machine and program it as follows; 
 
 Initial Denaturation: 95ºC for 5 min 
 
 Denaturation: 94ºC for 30sec 
Annealing: 58ºC for 30sec     35 cycles 
Extension: 72ºC for 30sec 
 
Final extension: 72º C for 5 min 
 
Loading: 
1. Prepared 2% agarose gel. [2gm of agarose in 100ml of 1X TAE 
buffer] 
2. Run electrophoresis at 50V till the dye reaches three fourth distances 
and observe the bands in UV Transilluminator. 
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Agarose gel electrophoresis: 
1. Prepared 2% agarose. (2gm agarose in 100ml of 1X TAE buffer and 
melted using micro oven) 
2. When the agarose gel temperature was around 60ºC, added 5μl of 
Ethidium bromide. 
3. Poured warm agarose solution slowly into the gel platform. 
4. Kept the gel set undisturbed till the agarose solidifies. 
5. Poured 1XTAE buffer into submarine gel tank. 
6. Carefully placed the gel platform into tank. Maintained the tank buffer 
level 0.5cm above than the gel. 
7. PCR Samples are loaded after mixed with gel loading dye along with 
10μl HELINI 100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 500bp, 
600bp, 700bp, 800bp, 900bp, 1000bp and 1500bp] 
8. Run electrophoresis at 50V till the dye reaches three fourth distance of 
the gel. 
9. Gel viewed in UV Transilluminator and observed the bands pattern. 
  
Results 
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RESULTS 
 
A total of 100 patients satisfying the inclusion criteria, admitted with signs 
and symptoms of invasive fungal infections (IFI) were included in the study. 
Out of 100 patients, 41 patients were found to be positive for fungal growth. 
 
Table-1 : 
Age and Sex Distribution among study population n=100 
 
AGE (YRS) 
RISK FACTORS 
TOTAL  
n (%) 
RENAL 
TRANSPLANT 
(RT) 
DIABETES 
MELLITUS 
(DM) 
CHEMO 
THERAPY 
(CT) 
RT 
& 
DM 
CT 
&DM 
M F M F M F M F M F 
18-20 - - - - 1 - - - - - 1 
21-30 3 3 2 2 11 5 - - - - 26 
31-40 9 6 5 1 3 5 - 1 - - 30 
41-50 2 3 3 2 2 5 2 - - - 19 
51-60 2 1 5 1 2 1 - - 1 - 13 
61-70 - - 2 2 4 - - - - - 8 
71-80 - - 1 1 - 1 - - - - 3 
TOTAL(%) 16 13 18 9 23 17 2 1 1 - 100 
P value 0.046 0.105 0.156 0.51 0.34  
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 The table 1 shows, the study consists of predominantly of males(60%) 
when compared to females(40%).Out of 100 patients, majority of them in the 
study belongs to the age group of 31-40 years(30%) followed by age group of 21-
30 years(26%) and 41-50yers(19%) 
 
CHART-1A 
Sex distribution among study population (n=100) 
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CHART-1B 
Age distribution among study population (n=100) 
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TABLE-2 
Duration of Immunosuppression favouring Fungal Infections (n=100) 
 
Period of 
Immuosuppression 
Criteria 
Total Renal 
Transplant 
(RT) 
Diabetes 
Mellitus 
(DM) 
Chemo 
therapy 
(CT) 
RT 
& 
DM 
CT 
& 
DM 
< 1 year 1 2 2 - - 5 
1-10 years 27 24 34 - 1 86 
>10 years 1 1 4 3 - 9 
Total 29 27 40 3 1 100 
P value 0.611 0.577 0.976 0.000 0.921  
 
 In the above table, duration of immunosuppression of 1-10 years 
showed increased incidence of IFI among 86% of patients. 
CHART 2 
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TABLE- 3 
Distribution and categorisation of IFI among study population (n=100) 
 
Categories 
Criteria 
Total 
RT DM CT 
RT & 
DM 
CT & 
DM 
Proven 4 4 4 2 1 15 
Probable 25 23 36 1 - 85 
Total (%) 29 27 40 3 1 100 
 
 
 The above table shows that incidence of Proven IFI was 15%. Most 
of the cases were under the category of Probable IFI (85%) 
 
CHART 3 
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TABLE-4 
 
Distribution of samples collected from study population 
with risk factors (n=100) 
 
Specimen 
Risk Factors 
Total 
n(%) 
Renal 
Transplant 
(RT) 
Diabetes 
Mellitus 
(DM) 
Chemo 
therapy 
(CT) 
RT & 
DM 
CT & 
DM 
Urine 22 12 13 2 - 49 
Sputum - 6 5 - - 11 
Br.Wash 5 8 8 - - 21 
Pl. Fluid - - 3 - - 3 
Blood - - 9 1 1 11 
BAL 2 1 2 - - 5 
TOTAL 29 27 40 3 1 100 
P value 0.013 0.209 0.002 0.725 0.147  
 
 Among immunosuppressive patients in the study, the majority of 
samples were urine (49%) followed by bronchial wash (21%), sputum 
(11%) and blood (11%). 
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CHART 4 : 
Distribution of samples collected from study population with risk factors 
(n=100) 
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TABLE-5 
Distribution of fungal isolates in clinical samples n=100 
 
Samples Growth No growth Total 
Urine 18  (43.90%) 31 49 
Sputum 6 (14.6%) 5 11 
Bronchial wash 10 (24.3%) 11 21 
Pleural fluid 1 (0.02%) 2 3 
Blood 3 (0.07%) 8 11 
BAL 3 (0.07%) 2 5 
TOTAL 41 59 100 
 
Among 100 patients in the study, 41 patients showed fungal growth. In the 
above table,majority of the growth was present in the urine sample(43.90%), 
followed by bronchial wash(24.3%%) and sputum (14.6%) 
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CHART 5  
 
 
  
44% 
15% 
24% 
0% 
0% 
0% 
Distribution of fungal isolates in clinical samples (n=100) 
Urine Sputum Bronchial wash Pleural fluid Blood BAL
60 
 
 
 
 
TABLE-6 
Distribution of Candida isolates and filamentous fungal isolates causing IFI 
 
Species 
Renal 
Transplant 
(RT) 
Diabetes 
Mellitus 
(DM) 
Chemo  
therapy (CT) 
RT 
& 
DM 
CT 
& 
DM 
Total 
(%) 
Candida 
albicans 
2 4 2 2 - 
10 
(24.4%) 
Candida non-
albicans 
3 4 5 - 1 
13 
(31.7%) 
Aspergillus 
fumigatus 
5 4 - - - 9(22%) 
Aspergillus  
flavus 
- 3 2 - - 
5 
(12.2%) 
Aspergillus  
niger 
- 2 - - - 
2 
(5%) 
Rhizopus - 2 - - - 2(5%) 
Total 10 19 9 2 1 41 
 
 Above table shows that among 41 isolates , majority of them were 
Candida non-albicans (31.7%) followed by Candida albicans (24.4%) and 
Aspergillus fumigatus (22%), Aspergillus flavus (12.2%), Aspergillus 
niger(5%) and Rhizopus(5%) 
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CHART 6  : 
 
Distribution of Candida isolates and filamentous fungal isolates causing 
invasive fungal infections (IFI) 
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TABLE 7A 
Distribution of Candida  isolates causing IFI in clinical samples 
Sample C.albicans C.nonalbicans Growth No growth 
Urine(49) 7(14.3%) 11(22.4%) 18(37%) 13(63%) 
Sputum(11) 1(9%) - 1(9%) 10(91%) 
Bronchial wash 
(21) 
- - - - 
Pl.fluid(3) 1(33.3%) - 1(33.3%) 2(66.6%) 
Blood(11) 1(9%) 2(18.2%) 3(27.3%) 8(72.7%) 
BAL(5) - - - 5(100%) 
Total 10(43.5%) 13(56.5%) 23 77 
 
 Above table shows, majority of them are C.non-albicans (56.5%) 
followed by C.albicans(43.5%) in clinical samples. 
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TABLE-7B 
Distribution of candida isolates causing IFI in clinical samples( n=23) 
 
Samples 
C. 
albicans 
C. 
tropicalis 
C. 
glabrata 
C. 
Parapsilosis 
C. 
krusei 
Growth 
No 
Growth 
Urine 
(49) 
7 
(14.3%) 
7 
(14.3% ) 
1 
(2%) 
2 
(4%) 
1 
(2%) 
18 
(37%) 
13 
(63%) 
Sputum 
(11) 
1 
(9%) 
- - - - 
1 
(9%) 
10 
(91%) 
Bronchial 
wash 
(21) 
- - - - - - - 
Pleural 
fluid 
(3) 
1 
(33.3%) 
- - - - 
1 
(33.3%) 
2 
(66.6%) 
Blood 
(11) 
1 
(9%) 
- 
2 
(18.2%) 
- - 
3 
(27.3%) 
8 
(72.7%) 
BAL 
(5) 
- - - - - - 
5 
(100%) 
Total 
10 
(43.5%) 
7 
(30.4%) 
3 
(13%) 
2 
(8.7%) 
1 
(4.3%) 
23 77 
 
 
 Above table shows that in urine sample, C.tropicalis(14.3%), 
C.albicans (14.3%) were reported commonly followed by C.parapsilosis 
(4%), C.glabrata (2%) and C.krusei (1%). 
 
 In blood culure, C.glabrata(18.2%) was commonly reported followed 
by C.albicans (9%). 
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TABLE-8 
Distribution of invasive mycoses among Proven and probable cases of IFI 
(n=41) 
 
Incidence of specific 
mycoses 
Growth (%) 
Candidiasis 23 56 
Aspergillosis 16 39 
Zygomycosis 2 5 
Total 41 100 
 
 In the above table, of 100 patients with Proven and Probable IFI, 
Candidiasis (56%) was most commonly encountered followed by 
Aspergillosis (39%) and Zygomycosis (5%). 
 
CHART 7 : 
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TABLE-9 
 
Antifungal susceptibility testing in candida species by disk diffusion method 
(n=23) 
 
SPECIES 
Fluconazole 
(25ug) 
Itraconazole 
(10 ug) 
Nystatin B 
(100ug) 
Voriconazole 
(1 ug) 
 
S R S R S R S R 
C.albicans 
(10) 
3 
(30%) 
7 
(70%) 
5 
(50%) 
5 
(50%) 
8 
(80%) 
2 
(20%) 
5 
(50%) 
5 
(50%) 
C.tropicalis 
(7) 
4 
(57.14%) 
3 
(42.86%) 
5 
(71.4%) 
2 
(28.6%) 
 
7 
(100%) 
- 
(0%) 
5 
(71.4%) 
2 
(28.6%) 
C.glabrata 
(3) 
- 
(0%) 
3 
(100%) 
- 
(0%) 
 
3 
(100%) 
3 
(100%) 
- 
(0%) 
- 
(0%) 
3 
(100%) 
C.parapsilosis 
(2) 
2 
(100%) 
- 
(0%) 
2 
(100%) 
- 
(0%) 
2 
(100%) 
 
- 
(0%) 
2 
(100%) 
- 
(0%) 
C.krusei 
(1) 
- 
(0%) 
1 
(100%) 
- 
(0%) 
1 
(100%) 
1 
(100%) 
- 
(0%) 
- 
(0%) 
1 
(100%) 
 
 
 In the above table, Antifungal susceptibility testing of Candida 
albicans showed highly sensitive to Nystatin(80%) followed by 
Voriconazole (50%), Itraconazole (50%) and Fluconazole(30%) and highly 
resistant to Fluconazole(70%) followed by Voriconazole(50%), Itraconazole 
(50%) and Nystatin(20%). 
 
 Candida tropicalis showed highly sensitive to Nystatin(100%) 
followed by Voriconazole (71.4%), Itraconazole(71.4%) and Fluconazole 
(57.14%) and highly resistant to Fluconazole (42.86%), Voriconazole 
(28.6%) and Itraconazole (28.6%). 
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 Candida glabrata showed highly sensitive to Nystatin (100%) and 
highly resistant to Fluconazole(100%), Voriconazole (100%) and 
Itraconazole (100%) 
 
 Candida parapsilosis showed highly sensitive to Fiuconazole(100%), 
Voriconazole(100%),Nystatin(100%),and Itraconazole(100%) 
 
 Candida krusei is highly sensitive to Nystatin (100%) and intrinsic 
resistant to Fluconazole (100%), Voriconazole (100%)and Itraconazole 
(100%). 
                                   
CHART-8A 
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CHART-8B 
Antifungal susceptibility  testing  in Candida  tropicalis 
by Disk Diffusion  method (n=7) 
 
 
 
 
CHART-8C 
Antifungal susceptibility  testing  in Candida  glabrata 
by Disk Diffusion  method (n=3) 
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CHART-8D 
Antifungal susceptibility  testing  in Candida  parapsilosis 
by Disk Diffusion  method (n=2) 
 
 
 
 
CHART-8E 
Antifungal susceptibility  testing  in Candida krusei 
by Disk Diffusion  method (n=1) 
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TABLE10 
 
Phenotypic characterisation- Phospholipase activity in Candida albicans 
(n=10) 
 
Phospholipase activity-Pz value 
Number of strains showing 
Phospholipase activity (number of 
strains tested)         n=23(%) 
1 (Negative) - 
< 0.90-0.99 (+) 1 
0.80-0.89(++) 2 
0.70-0.79(+++) 2 
<0.70(++++) 5 
 
 
 
TABLE-11 
 
Phenotypic characterisation - Phospholipase activity in Candida tropicalis 
(n=7) 
 
Phospholipase activity-Pz value 
Number of strains showing 
Phospholipase activity (number of 
strains tested)         (n=7) 
1 (Negative) 1 
< 0.90-0.99 (+) - 
0.80-0.89(++) - 
0.70-0.79(+++) 1 
<0.70(++++) 5 
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Table-12 
 
Phenotypic characterisation- Phospholipase activity in Candida glabrata 
(n=3) 
 
Phospholipase activity-Pz value 
Number of strains showing 
Phospholipase activity (number of 
strains tested)         n=3(%) 
1 (Negative) 2 
< 0.90-0.99 (+) - 
0.80-0.89(++) 1 
0.70-0.79(+++) - 
<0.70(++++) - 
 
 
Table-13 
 
Phenotypic characterisation- Phospholipase activity in Candida parapsilosis 
(n=2) 
 
Phospholipase activity-Pz value 
Number of strains showing 
Phospholipase activity (number of 
strains tested)       (  n=2) 
1 (Negative) 1 
< 0.90-0.99 (+) - 
0.80-0.89(++) 1 
0.70-0.79(+++) - 
<0.70(++++) - 
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TABLE-14 
 
Phenotypic characterisation- Phospholipase activity in Candida krusei 
(n=1) 
 
Phospholipase activity-Pz value 
Number of strains showing 
Phospholipase activity (number of 
strains tested)         n=1 
1 (Negative) - 
< 0.90-0.99 (+) - 
0.80-0.89(++) - 
0.70-0.79(+++) 1 
<0.70(++++) - 
 
 
 From the above tables (10,11,12,13,14). 5 isolates of C.albicans 
showed Pz value of < 0.70(++++) with high phospholipase activity. 5 
isolates of C.tropicalis showed Pz value of <0.70(++++) with high 
production of phospholipase activity. 
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TABLE -15A  
 
Phenotypic characterisation- Hemolysin activity in Candida species 
(n=23) 
 
Candida spp Alpha hemolysis Beta hemolysis 
Gamma 
hemolysis 
C.albicans
(10)
 2(20%) 6(60%) 2(20%) 
C.nonalbicans
(13)
 2(8.7%) 7(54%) 4(30.8%) 
 
 From the above table, Among the Candida species,the 
higher rate of alpha hemolysis, beta hemolysis and gamma hemolysis  was 
observed in C.albicans (20%), C.albicans (60%) and Candida non-
albicans(30.8%) respectively..  
CHART-9A 
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TABLE-15B 
 
Phenotypic characterisation- Hemolysin activity in Candida species 
(n=23) 
 
Candida Species 
Hemolysis 
Alpha Hemolysis Beta Hemolysis 
Gamma 
Hemolysis 
C.albicans(10) 2(20%) 6(60%) 2(20%) 
C.tropicalis(7) 1(14.3%) 4(57.1%) 2(28.6%) 
C.glabrata(3) 1(33.3%) 1(33.3%) 1(33.3%) 
C.parapsilosis(2) - 1(50%) 1(50%) 
C.krusei(1) - 1(100%) - 
Total 4(17.4%) 13(56.5%) 6(26%) 
 
 
 From the above table, Alpha hemolysis, Beta hemolysis and 
Gamma hemolysis was observed in 17.4% , 56.4% and 26% of the candida 
isolates respectively. 
 Among the C.albicans and C.non albicans spp, the higher rate of 
alpha hemolysis, beta hemolysis and gamma hemolysis were observed in 
C.glabrata(33.3%) , C.krusei(100%) and C.parapsilosis(50%) respectively.  
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TABLE-16 
 
Molecular analysis-  Identification of ERG11 gene among  fluconazole 
resistance candida species  (n=10) 
 
Candida species 
Number of Candida isolates 
with Fluconazole resistance 
ERG11 gene 
positive 
Candida albicans 7 2 
Candida tropicalis 3 - 
 
 
 Fluconazole resistance among Candida species tested by PCR showed the 
presence of ERG11 gene in 2 isolates of Candida albicans. 
 
ID ERG11 
1 Positive 
2 Negative 
3 Positive 
4 Negative 
5 Negative 
 
ERG11 gene=  1,3 Positive 
 
ID ERG11 
6 Negative 
7 Negative 
8 Negative 
9 Negative 
10 Negative 
 
ERG11 gene =  All Sample Negative 
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CHART 10 
 
Molecular analysis- Identification of ERG11 gene among fluconazole 
resistance Candida species (n=10) 
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TABLE-17 
Clinical outcome of the study cases 
 
 
FOLLOW UP 
PROVEN IFI 
n=15 
PROBABLE IFI 
n=85 
TOTAL(%) 
Cured 10 58 68 
Relapse 2 11 13 
Expired 3 8 11 
Lost to follow up - 8 8 
 
 The overall mortality seen in this study was 11% and the cases were 
proven IFI and probable IFI. Mortality was seen among cancer patients on 
chemotherapy with neutrophenia due to candidemia, uncontrolled Diabetes 
mellitus with Rhizopus and invasive Aspergillosis. 
 
CHART-11 
Clinical outcome  of the study cases 
 
 
  
10 2 3 0 
58 
11 8 8 
0
10
20
30
40
50
60
70
Cured Relapse Expired Lost to follow up
 Proven IFI (n=15) Probable IFI (n=85)
Discussion 
  
78 
 
 
DISCUSSION 
 
 Invasive fungal infections (IFIs) are increasing in incidence among 
patients with immunocompromised state
[62]
. The morbidity and mortality is 
caused by IFI. 
 
 100 immunocompromised patients with clinical suspicion of  having 
fungal infections were included in the study. Immunocompromised patients 
selected under the study were acute hematological malignancy with 
intensive chemotherapy, cancer patients, complicated intensive care 
patients, patients on long term steroids and antibiotic therapy, Renal 
transplant recipients on immunosuppressive therapy and Diabetes mellitus.  
 
 This cross sectional study was conducted in the institute of 
Microbiology in association with Department of Hematology, Department 
of Medical oncology and Institute of Internal Medicine, Madras medical 
college and RGGGH,Chennai-3 for a period of one year from March 2017 
to February 2018. 
 
 Most of the patients affected by IFI in this study(Table 1) were in the 
age group of 31-40 years (30%) followed by age group of 21-30 years 
(26%).Among the study population , majority of the patients were  
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males(60%).Similar findinds have been recorded by Milton camplesi junior 
et al
[63]
. The mean age of the patients was 35.7 years, with a range of 21-60 
years. Similar findings have been recorded by Kontoyiannis et al which 
showed that 60% of the patients were males
[60]
. 
 
 Patients with duration of immunosuppression of 1-10 years showed 
increased incidence of IFI in this study (Table 2). As the duration of 
immunosuppressed state increases, susceptibility of infection also increases. 
Similar findings have been recorded by Kontoyiannis et al,who found a 
median duration for development of IFI in transplant recepients was more 
than 1 year.
[60] 
 
 Among 100 cases in the present study, 41 patients showed fungal 
growth. According to European organisation for research and treatment of 
cancer (EORTC) criteria,among these 100 patients ,15% were  Proven and 
85% were Probable IFI (Table 3). Kontoyiannis et al ,studied on patients 
with IFI for a period of  5 years reported 56% were Proven and 44% were 
probable IFI 
[60]
 
 
 In the present study, majority of patients of IFI presented with 
symptoms of urinary tract infections, sepsis and respiratory infections. So, 
most of the samples collected were urine, bronchial wash, sputum, blood 
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and bronchoalveolar lavage(Table 4).Pagano et al studied patients with IFI 
and reported most common system involved was respiratory tract
[66]
 
 
 In the present study,  among the 41 fungal isolates ,(Table 6) majority 
of them were Candida non-albicans (31.7%) followed by Candida albicans 
(24.4%), Aspergillus fumigatus (22%), Aspergillus flavus (12.2%), 
Aspergillus niger (5%) and Rhizopus (2%). Pfaller et al also reported 
increase in Candida non-albicans spp and higher mortality among the 
patients.
[2] 
 
 Candida species are usually colonizers. So, if isolated their 
significance should be defined. Candida spp from blood or on repeated 
isolation is taken as pathogen. In the present study(Table 7A ),among 
invasive candidiasis, majority of them were Candida non-albicans (56.5%) 
followed by Candida albicans (43.5%) in clinical samples. In this study, 
(table 7 B), in urine samples, among candida species, majority of them were 
Candida tropicalis (14.3%), Candida albicans (14.3%) followed by Candida 
parapsilosis (4%), Candida glabrata (2%) and Candida krusei (1%). 
Chakrabarti et al 
[64]
 
 
 Showed high rate of isolation of Candida tropicalis in intensive care 
unit patients. 
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 In this study (Table 7B), In blood culture,the most common Candida 
spp isolated were Candida glabrata (18.2%) followed by Candida albicans 
(9%). Candida glabrata has emerged as potentially resistant invasive fungal 
infection 
[67,68,69]
. Trick et al 
[69]
 in united states have demonstrated 
C.glabrata has increased incidence in intensive care unit patients. Two 
prospective studies by Tortorano et al 
[70]
 also reported C.glabrata in blood 
culture. 
 
 In the present study (Table 8) Invasive Candidiasis was present in 
56% of patients followed by Aspergillosis (39%) and Zygomycosis (5%). 
Similar findings are observed by Chakrabarti et al 
[64] 
and Enoch et al 
[65]
. 
Chakrabarti et al showed invasive candidiasis as the most common mycotic 
infection across India. Kauffman et al 
[71]
 also showed that the most 
common IFIs were the invasive candidiasis followed by Aspergillosis. 
 
 In the present study (Table 9)  Antifungal susceptibility testing was 
performed in candida species by Disk diffusion method.Among 10 Candida 
albicans, Fluconazole resistance was 70% followed by Itraconazole (50%), 
Voriconazole (50%) and Nystatin(20%). Among 7 Candida tropicalis, 
Fluconazole resistance was 42.86% followed by Itraconazole (28.6%) and 
Voriconazole (28.6%). Brekow et al 
[72]
 showed increase in Fluconazole 
resistancein Candida albicans and Candida non-albicans. 
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  In the present study, the virulence characters of Candida species such 
as Phospholipase activity and hemolysin activity were determined.  
(Table 10,11). 5 isolates of C.albicans showed Pz value of < 0.70(++++) 
with high phospholipase activity. 5 isolates of C.tropicalis showed Pz value 
of <0.70(++++) with high production of phospholipase activity. Das et al 
[58]
 
showed similar finding with high production of phospholipase activity 
among C.albicans. 
 
 In the present study,(Table 15A and 15B) alpha hemolysis, beta 
hemolysis and gamma hemolysis was observed in 17.4% , 56.5% and 26% 
of the candida isolates respectively. Among the Candida species, the higher 
rate of alpha hemolysis, beta hemolysis and gamma hemolysis  was 
observed in C.albicans (20%), C.albicans (60%) and Candida non-albicans 
(30.8%) respectively. Among the C.albicans and C.non albicans spp, the 
higher rate of alpha hemolysis, beta hemolysis and gamma hemolysis were 
observed in C.glabrata(33.3%), C.krusei (100%) and C.parapsilosis (50%) 
respectively. Nader Davari et al
[59]
 showed similar production of alpha 
hemolysia,beta hemolysis and gamma hemolysis among the Candida 
isolates. 
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 (Table 16 ) In the present study, Fluconazole resistance among the 
Candida species tested by PCR showed the presence of ERG11 gene in 2 
isolates of C.albicans. 
 
 Berkow et al 
[71]
 showed the presence of ERG11 gene in C.albicans. 
 
 (Table 17)The over all mortality seen in this study was 11% and the 
cases had Proven IFI and Probable IFI. 
 
 Mortality was seen among cancer patients on chemotherapy with 
neutropenia due to candidemia caused by drug resistant C.albicans, 
uncontrolled Diabetes mellitus with Rhizopus and Aspergillosis.Fleveri et 
al
[73]
 showed mortality rate of 30-60% in patients with candidemia. Ryuichi 
Hirano et al 
[74]
 showed over all 30 day mortality rate of patients with 
candidemia(26%). Carolina Garcia-vidal et al 
[75]
 showed over all (90 days) 
mortality of patients with Aspergillosis( 60.5%). 
  
Summary 
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SUMMARY 
 
 The study was done at Institute of Microbiology , RGGGH, from  
March 2017 to February 2018.The study group included 100 patients. 
The patients selected under the study were acute hematological 
malignancy with intensive chemotherapy, complicated Intensive care 
unit patients,patients on long term steroids and antibiotic therapy, 
Renal transplant recepients on immunosuppressive therapy and 
Diabetes mellitus. 
 There were 60% males and 40% females in the clinically diagnosed 
cases of invasive fungal infections. 
 The most common age group affected by fungal infection was found 
to be between 31-40 years . 
 Among the study population,41% of the patients showed fungal 
growth. 
 Proven IFI was found in 15% of the cases and remaining were under 
the category of probable IFI(85%) 
 Among the 41 fungal isolates, majority of them were Candida  
non-albicans(31.7%) followed by Candida albicans (24.4%), 
Aspergillus fumigatus (22%), Aspergillus flavus (12.2%),Aspergillus 
niger (5%) and Rhizopus(2%). 
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 Among the invasive Candidiasis, majority of them were Candida non-
albicans (56.5%) followed by Candida albicans (43.5%) in clinical 
samples.   
 In urine samples, among the Candida species, majority of them were     
Candida tropicalis (14.4%), Candida albicans (14.4%), followed by      
Candida parapsilosis(4%), Candida glabrata(2%) and Candida 
krusei(1%). 
 In blood culture, the most common Candida species isolated were 
Candida  glabrata (18.2%) followed by Candida albicans (9%) 
 Among the patients with Proven and Probable IFI , Candidiasis 
constitutes 56% followed by Aspergillosis (39%) and Zygomycosis 
(5%). 
 Antifungal susceptibility testing was performed for Candida isolates 
by Disk diffusion method.Fluconazole resistance was observed 
among C.albicans and C.tropicalis with 70% and 42.86% 
respectively. 
 Virulence characters such as Phospholipase and hemolysin activity 
was tested for Candida isolates. 
  C.albicans and C.tropicalis showed high production of Phospholipase 
activity. 
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 Hemolysin production among Candida species, higher level of 
production of  β hemolysis was observed in Candida albicans (60%) 
and Candida non albicans(54%). 
 Hemolysin production among Candida non-albicans species, higher 
level of   β hemolysis was observed in C.krusei(100%) . 
 Fluconazole resistance among the Candida species tested by PCR 
showed the presence of ERG11 gene in 2 isolates of C.albicans. 
 The clinical outcome of the patients included in the study was 
determined. 
 The overall mortality seen in this  study was 11% and the cases had 
Proven IFI and Probable IFI. 
  
Conclusion 
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CONCLUSION 
 
 Invasive fungal infections are a major cause of morbidity and mortality 
in immunocompromised patients. 
 The patients with suspected IFI in the study population was in the age 
group of  
31-40 years and they were predominantly males . 
 Etiological agent was identified in 41% of infected patients. 
 On categorization, 15% had Proven IFI and 85% had Probable IFI. 
 The leading cause of IFI was invasive Candidiasis followed by 
Aspergillosis. 
 Invasive Candidiasis was mainly caused by Candida non-albicans 
followed by Candida albicans. 
 Aspergillus fumigatus was the commonest spp causing Aspergillosis in 
IFI. 
 Virulence characters such as Phospholipase and hemolysin activity were 
found among Candida isolates. 
 Higher production of Phospholipase and hemolysin activity was shown 
in Candida albicans. 
 Canida non- albicans also showed higher level of Phospholipase and 
hemolysin activity. 
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 Antifungal susceptibility testing for Candida spp by Disk diffusion 
method showed higher resistance to fluconazole in C.albicans followed 
by C.tropicalis 
 Fluconazole resistance tested by PCR in Candida albicans showed the 
presence of ERG11 gene. 
 Increasing rate of fluconazole resistance among C.albicans may be due to 
frequent use of these agents in the prophylaxis of fungal infections in 
immunocompromised patients. 
 So, the best approach to the optimal management of fungal infection is 
early detection and identification of the causal agent, so that appropriate 
treatment can be initiated as soon as possible in immunocompromised 
patients.  
  
 
Colour Plates 
  
1. Candida albicans 
 
 
 
Growth of C.albicans on 
Sabouraud’s Dextrose Agar 
Gram stain showing budding yeast 
cells 
 
 
 
 
 
 
CHROM AGAR showing - C.albicans 
 
 
   
Germ tube test - C.albicans  
showing Germ tube 
Assimilation test - C.albicans  
 
 
 
 
 
 
CHROM Agar showing Candida species 
 
  
 2. Candida tropicalis 
 
 
 
 
  
 
Growth of C.tropicalis on 
Sabouraud’s Dextrose Agar 
Gram stain shows budding yeast 
cells 
 
 
 
 
CHROM AGAR showing - C.tropicalis 
 
 
 
 3. Candida glabrata 
 
 
 
  
 
Growth of C.glabrata on Sabouraud’s 
Dextrose Agar 
Gram stain showing budding yeast 
cells 
 
 
 
 
CHROM AGAR showing - C.glabrata 
 
 
 
 4. Antifungal susceptibility testing by Disk diffusion method 
Fluconazole sensitive candida species 
 
 
 
Fluconazole resistance candida species 
 
 
  
 5. Phospholipase activity in Egg Yolk Medium – Candida species 
 
  
 
 
 
 
6. Hemolysin activity in Blood Agar Plate - Candida species 
 
 
 
 
  
 7. Aspergillus fumigatus 
 
 
 
 
Sabouraud’s Dextrose Agar showing 
smoky green colonies 
LPCB mount showing conidia 
arising from upper third of vesicle 
 
8. Aspergillus flavus 
 
 
 
 
 
 
Sabouraud’s Dextrose Agar showing 
yellow green colonies 
LPCB mount showing conidia 
arising from entire vesicle 
 
  
 9. Aspergillus niger 
 
 
Sabouraud’s Dextrose Agar showing black colonies 
 
 
 
 
LPCB mount showing black conidia arising from entire vesicle 
 
 10. Rhizopus 
 
 
 
 
 
 
KOH Mount – showing aseptate 
hyphae 
Sabouraud’s Dextrose Agar 
showing salt and pepper appearance 
colony 
 
 
 
 
LPCB mount showing Sporangium, Rhizoids 
 
 
11. Molecular  analysis  - Identification of ERG 11 gene among 
Fluconazole resistance  Candida  species. 
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Annexures 
 APPENDIX- I   
ABBREVIATIONS 
BG   -   1/3-B-D-Glucans 
CT  -   Computed Tomography 
CNS   -   Central Nervous System; 
ELISA   -   Enzyme – Linked ImmunoSorbent Assay 
IFD   -   Invasive Fungal Disease 
IFI   -   Invasive Fungal Infections  
HRCT   -    High-Resolution Computed Tomography  
MRI   -   Magnetic Resonance Imaging. 
AFST   -   AntiFungal Susceptibility Testing 
CLSI   -  Clinical Laboratory Standard Institute 
SDA - Sabouraud Dextrose Agar 
MIC   -   Minimum Inhibitory Concentration 
AIDS   -   Acquired ImmunoDeficiency Syndrome 
IDSA  - Infectious Disease Society of America 
LPCB   -   LactoPhenol Cotton Blue 
  
 APPENDIX II 
 
A).STAINS AND REAGENTS 
 
Gram staining: 
 Methyl violet(2%)-10g of Methyl violet in 100 ml Absolute alcohol in 1 
litre of Distilled      water.(primary stain) 
 Grams Iodine-10g Iodine in 20 g KI (fixative) 
 Acetone-Decolourizing agent. 
 Carbol fuchsin(1%)-Secondary stain. 
 
B.MEDIA USED 
1.SABOURAUD DEXTROSE  AGAR  WITH  ANTIBIOTICS: 
 
INGREDIENT          Gm/ltr 
 
Peptone          10 gms 
Dextrose         40 gms 
Agar               20 gms 
Distilled water  1000 gms 
Gentamicin         20 mg 
Final pH was  adjusted to  5.6 
      The  above ingredients  were  reconstituted in  one  litre  of   distilled  water 
.Dissolve  the powder  water  by  boiling. Gentamicin  is added  to  the  boiling  
medium.The  medium  was then  removed  from  heating ,mixed  well and then  
 dispersed  in  tubes  and  autoclaved  at  121oC for  15  minutes   and the  final  pH 
was   adjusted  to  5.6.The  tubes  were  cooled  in  slanted   position  and  later   
the  slants  were  stored in  refrigerator.   
2.YEAST  NITROGEN BASE  MEDIUM (DEHYRATED  MEDIA): 
INGREDIENTS GMS/L INGREDIENTS GMS/L 
Ammonium 
sulphate 5.000 Niacin 0.0004 
L-Histidine 
hydrochloride 0.010 
p-Amino benzoic 
acid (PABA) 
0.0002 
 
DL-Methionine 0.020  
Pyridoxine 
hydrochloride 
0.0004 
 
DL-Tryptophan 0.020  
Riboflavin 
(Vitamin B2) 
0.0002 
 
Biotin 0.000002  
Thiamine 
hydrochloride 
0.0004 
 
Calcium 
pantothenate 
0.0004 
 Boric acid 
0.0005 
 
Folic acid 0.00002 Copper  sulphate  0.00004 
Inositol 0.002  Potassium iodide 0.0001 
Ferric chloride 0.0002  
Manganese 
sulphate 
0.0004 
 
Sodium molybdate 0.0002  Zinc sulphate 
0.0004 
 
Monopotassium 
phosphate 
1.000 
 
Magnesium 
sulphate 
0.500 
 
Sodium chloride 0.10 Calcium chloride 0.100  
Dissolve  6.7 gms  of  media  in  100 ml   0f  distilled  water. Serilise  by  
filteration  and  store  at  4oC. 
 3.CHROM   AGAR CANDIDA  MEDIUM: 
Ingredients                                             Gms/L 
Peptone,                                                  15 gms 
Yeast extract                                           4 gms 
Dipotassium hydrogen phosphate           1. gms 
Chromogenic mixture                              7.22 gms 
Chloramphenicol                                     0.5 gms 
Agar                                                         15 gms 
pH  6.3±0.2  at  25°C 
Suspend 42.72 grams in 1000 ml distilled water. Heat to boiling to dissolve the 
medium completely. DO NOT AUTOCLAVE. Cool to 45-50°C. Mix well and 
pour into sterile Petri plates. 
 
4. MUELLER  HINTON AGAR: 
Ingredients                                  Gms / Litre 
Beef infusion                              300ml 
Casein  hydrosylate                     17.5gm 
Starch                                           1.5gm 
Agar                                             10gm 
Final pH 7.4±0.1  
Sterilize  by  autoclaving   at  121°C  for 15 minutes 
 
5. EGG  YOLK MEDIUM 
Ingredients:                                        Gms / Litre 
SDA                                            65g 
NaCl                                               58.4g 
CaCl2                                              5.5 g 
                                          
 The egg yolk medium consisted of 65g SDA, 58.4g NaCl and 5.5 g CaCl2 
dissolved in 980ml distilled water and sterilized at 121℃ for 15 minutes.Egg yolk 
was centrifuged at 5000 g for 30 minutes and 2 ml of supernatant was added to 
medium cooled at 45-50℃ 
 
 
  
 ANNEXURE –I    
CERTIFICATE OF APPROVAL 
 
 
 ANNEXURE –I I 
PROFORMA 
 
 Name :                                                                      IP  NO: 
 Age:                                                                          Ward: 
 Sex: 
 Occupation: 
 Address: 
 
 Presenting complaints 
 Personal history 
 Past history 
 
 Prior antibiotic  therapy/antifungal therapy 
 
 Clinical Diagnosis: 
 
 Microbiological  investigation : 
 Microscopy - Gram staining :   
                          - KoH Mount  : 
                    -  Negative staining : 
 
 Culture : Sabouraud’s Dextrose Agar Media: 
 Organism identified   : 
 
 Antifungal sensitivity pattern  
 Candida species identification- phenotypic 
                                                 -Genotypic- PCR 
 
 
 ANNEXURE –III 
PATIENTS CONSENT FORM 
 
  STUDY TITLE : A study on the pattern of fungal infections and clinical 
profile in immunocompromised patients with special reference to 
characterisation and molecular study of candida species  in a tertiary care 
Hospital. 
 
 I…………………………………………, hereby give consent to 
participate in the study conducted  by Dr.M.Akilamani, Post graduate at Institute 
of Microbiology, Madras Medical College, Chennai and to use my personal 
clinical data and the result of investigations for the purpose of analysis and to 
study the nature of the disease,  
I also give consent to give my clinical Specimen (sputum, endotracheal aspirate, 
bronchial wash, pleural fluid, ascitic fluid, peritoneal dialysis fluid, wound swab, 
cerebrospinal fluid, urine, pus, blood) for further investigations. I also learn that 
there is no additional risk in this study. I also give my consent for my investigator 
to publish the data in any forum or journal. 
 
 
 
   
Signature/ Thumb impression                                   Place                             Date 
Of the patient/ relative 
 
 
Patient Name & Address: 
 
Signature of the investigator: 
 
 
Signature of guide: 
 
 
  
 ANNEXURE –IV 
INFORMATION SHEET 
STUDY TITLE : A study on the pattern of fungal infections and clinical 
profile in immunocompromised patients with special reference to 
characterisation and molecular study of candida species  in a tertiary care 
Hospital. 
 
INVESTIGATOR   : Dr.M.Akilamani, 
                                    First Year Post Graduate Student, 
     Institute of Microbiology, 
   Madras Medical College, 
   Chennai - 600003 
 
GUIDE    : Dr. C.P.Ramani M.D., 
                                      Professor of Microbiology, 
                                      Institute  of  Microbiology, 
                                      Madras  Medical  College, 
                                      Chennai - 600003 
• Immunocompromised patients are at high risk for fungal  infections. so, early 
diagnosis will be helpful to start specific antifungal therapy. 
• The identification of Candida species is very important in the  diagnostic 
laboratory, because such identification shows prognostic and therapeutic 
significance, allowing the specific  antifungal therapy.  
• I am going to collect sputum, endotracheal aspirate, bronchial wash,pleural 
fluid, ascitic fluid,peritoneal dialysis fluid,blood, urine, pus and cerebrospinal 
fluid samples for this study and process them accordingly.100 patients are 
included in this study after getting informed consent only. 
• I am going to isolate and identify the fungal etiology  in immunocompromised 
patients.  I am going to study the clinical profile of fungal infections and 
antifungal susceptibility pattern in candida. I am going to do the 
characterisation and perform molecular study of candida species in this tertiary 
hospital.  
• This study is entirely voluntary and patient can withdraw any time from this 
study. Extra cost will not be incurred to the patients in this study. Any doubt 
regarding this study will be willingly clarified. Results of the study will be 
published. In case of any doubt please contact Dr. M.Akilamani,  Cell: 
9894277044. 
  
  
  
Alpha Beta
Gamm
a
1 Natraj 76 M Urine 2 +
Frequency of micturition, 
abdominal pain
T2 DM / UTI - Blue C.tropicalis + - - - + R R S R 4 + +
2 Vishnu 35 M Urine 4 + Fever T2 DM/UTI - Blue C.tropicalis + - + R R S R 3 + +
3 Karthik 25 M Sputum 3 + Fever ALL NG
4 Dhanaivel 24 M Blood 2 + Fever ALL NG
5 Krishnan 65 M Br.Wash 5 + Hemoptysis Breathlessness
T2 DM/PT 
sequelae/R 
Fibrocavity
NG
6 Krishnamoorthy 55 M Sputum 4 + Dry cough breathlessness
T2 DM / PTB  (R) 
LL with 
consolidation
Aspergillus 
fumigatus
7 Rajeswari 26 F Sputum 2 + Fever ALL NG
8 Karthikeyan 23 M Urine 5 + Fever UTI NG
9 Raja 60 M Urine 6 + Fever T2DM/UTI + Green C.albicans + + + S S S S 1 + +
10 Pattaleswari 56 F Urine 2 + Fever UTI + Green C.albicans + + + S S S S 2 + +
11 Jafarudeen 30 M Urine 3 + Fever Abdominal Pain T2DM/UTI NG
12 Gandhimathi 30 F Urine 6 + Fever Sepsis - Cream C.Parapsilosis + + S S S S Negative +
13 Narasimman 45 M Sputum 3 + Hemoptysis Breathlessness
T2 DM/ Invasive 
Aspergilloma
A.niger
14 Akash 25 M sputum 4 + Fever Breathlessness ALL NG
15 Bharath 20 M Blood 3 + Fever
AML / 
Pancytopenia
- Purple C.glabrata + + R R S R 2 + +
16 Venkatesan 22 M BAL 1 + Fever ALL/Pneumonia NG
17 Baskaran 55 M BAL 1 + Fever CLL/Pneumonia NG
18 Shanmugam 55 M Blood 2 + + Fever
ALL/Sepsis/Neutro
penia
- Purple C.glabrata + + R R S R Negative +
19 Arumugam 27 M Urine 1 + Fever AML NG
20 Munusamy 66 M Urine 2 + Fever
NHL / 
Pancytopenia
NG
21 Brindha 25 F B.Wash 2 + Hemoptysis Breathlessness
T2DM / (L) UL 
Cavity
NG
22 Balaji 25 M Urine 4 + Fever AML with relapse NG
23 Rakesh Sivabalan 26 M Urine 1 + Fever ALL NG
24 Kolanjinathan 43 M B.Wash 2 + Fever   Hemoptysis
T2DM/ Invasive 
Aspergilloma
NG
25 Antonydoss 55 M Sputum 1 + Breathlessness
T2DM 
/Pneumonia
NG
Duration 
of illness 
(yrs)
Renal Tx DM CT Symptoms Diagnosis Hemolysin Activity
Carbohydrate Assimilation 
test 
Antifungal 
Susceptiblity Test
Phenotypic Methods - Candida
S.
No.
Name Age Sex Sample
MASTER CHART
Germ 
Tube 
Test
Chrom Agar Organism Death
Phospholipase ActivityXY MEL RAFFI LAC Suc FLU ITR NYS VOR
Molecular Method Candida
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Phospholipase ActivityXY MEL RAFFI LAC Suc FLU ITR NYS VOR
Molecular Method Candida
26 Lakshmi 42 F B.Wash 6 Months + Hemoptysis Breathlessness
T2DM/ (L) 
Fibrocavity
NG
27 Annadurai 40 M Sputum 1 +
Fever Hemoptysis 
Breathlessness
T2DM / PTB (R) LL 
Consolidation
A.Flavus
28 Jasmin Mary 57 F Urine 2 + Fever T2DM/UTI + Green C.albicans + + + R R S R 2 + +
29 Lalitha 45 F Urine 1 + Fever Abdominal Pain UTI NG
30 Semandhammal 65 F Sputum 2 +
Fever Hemophysis 
Breathlessness
T2DM/PTB (R) LL 
Consolidation
A.flavus
31 Madeswari 47 F Urine 2 + Frequency of micturition NHL / UTI NG
32 Lakshmi 42 F Blood 11 + Fever AML NG
33 Pappathi 75 F Urine 2 + Fever T2DM/UTI + Green C.albicans + + + R R R R 4 + + +
34 Ashok Kumar 31 M B.Wash 4 + Hemoptysis Breathlessness
T2DM/PT / (R) UL 
consolidation
A.flavus
35 Lokesh 65 M Blood 3 + Fever
NHL / 
Pancytopenia
NG
36 Madhavan 70 M Blood 12 + Fever AML NG
37 Prakash 47 M Urine 5 + Fever Sepsis - Cream C.Parapsilosis + + S S S S 2 + +
38 Ramesh 36 M B.Wash 4 + Fever Breathlessness
T2DM / (R) LL 
Consolidation
Rhizopus sp +
39 Susheela 40 F Urine 11 + + Fever Abdominal Pain T2 DM / UTI NG
40 Anitha 50 F Urine 3 + Fever Abdominal Pain UTI NG
41 Padma 54 F Urine 13 + Fever Abdominal Pain T2 DM / UTI C.tropicalis + + S S S S 4 + +
42 Sendhil 42 M Blood 2 + Fever AML NG
43 Abitha 25 F Urine 3 + Abdominal Pain
ALL / Neutropenia 
High grade T-cell 
lymphoma
NG
44 Nandhini 21 F Urine 1 + Fever AML NG
45 Dhanush 25 M Urine 5 + Fever Dysuria UTI NG
46 Sivakumar 33 M Urine 4 + Abdominal Pain CKD NG
47 Bakkiya Lakshmi 23 F Urine 3 + Fever Dysuria UTI NG
48 Nethaji 68 M Urine 1 + Frequency of micturition fever T2DM / UTI Candida albicans + + + R S S S 4 + +
49 Anbazhagan 50 M Blood 17 + + Fever Abdominal Pain T2DM / UTI C.albicans + + + S S S S 3 + +
50 Lokesh 45 M Urine 2 + Fever Dysuria UTI NG
51 Semandhammal 45 F Urine 4 + Abdominal Pain
NHL / 
Pancytopenia
NG
Alpha Beta
Gamm
a
Duration 
of illness 
(yrs)
Renal Tx DM CT Symptoms Diagnosis Hemolysin Activity
Carbohydrate Assimilation 
test 
Antifungal 
Susceptiblity Test
Phenotypic Methods - Candida
S.
No.
Name Age Sex Sample
Germ 
Tube 
Test
Chrom Agar Organism Death
Phospholipase ActivityXY MEL RAFFI LAC Suc FLU ITR NYS VOR
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52 Sumathi 35 F B.Wash 2 + Breathlessness
T2 DM / Invasive 
aspergillosis
A.Fumigatus +
53 Lakshmi 42 F Urine 8 + Abdominal Pain UTI NG
54 Padmavathy 75 F Urine 13 + Fever AML - Blue C.tropicalis + - - - + S S S S Negative +
55 Vijayan 36 M BAL 6 + Breathlessness Pneumonia A.Fumigatus +
56 Velaisamy 52 M Urine 6 + Dysuria UTI NG
57 Kowsalya 45 F Urine 1 + Fever Dysuria T2 DM / UTI + Green C.albicans + - - + + R R S R 3 + +
58 Madhavan 40 M BAL 4 + Breathlessness Pneumonia A.Fumigatus +
59 Valtarvettrivel 24 M Urine 6 + Fever AML NG
60 Kodeswari 24 F Urine 2 + Abdominal Pain
NHL / UTI / 
Pancytopenia
- Blue C.tropicalis + - - - + S S S S 4 + +
61 Kumaravel 42 M Urine 6 + Abdominal Pain UTI - - NG
62 Raja 26 M Urine 4 + Dysuria NHL / UTI - - NG
63 Ranjani 27 F Br.Wash 5 + Breathlessness R Consolidation - - NG
64 Poongodi 37 F Br.Wash 2 + Breathlessness Pneumonia - - NG
65 Selvam 40 M B.Wash 8 + Breathlessness
T2 DM / Invasive 
aspergillosis
- - A.Fumigatus
66 Meena 31 F Urine 1 + Dysuria UTI - - NG
67 Ramalingam 65 M Urine 2 + Fever ALL - - NG
68 Sumathi 68 F BAL 5 + Breathlessness
T2 DM / Invasive 
aspergillosis
- - A.Fumigatus
69 Jasmin 58 F Blood 13 + Fever
AML / 
Pancytopenia
- - NG
70 Ashok Kumar 31 M Blood 1 + Fever
NHL / 
Pancytopenia
- - NG
71 Ramesh 35 M Urine 2 + Fever Dysuria UTI - Blue C.tropicalis + - - - + S S S S 4 + +
72 Lalitha 42 F Sputum 1 + Fever Breathlessness AML NG
73 vishnu 49 M Br.Wash 1 + Breathlessness Ca. Lung NG
74 Priya 36 F Sputum 3 + Fever ALL/Neutropenia + Green C.albicans + + - - + + R R R R 4 + + +
75 Kalpana 39 F Br.Wash 6 Months + Breathlessness/Dysuria L Consolidation NG
76 Mohan 52 M Pleural Fluid 1 + Fever Breathlessness Ca. Lung + Green C.albicans + - - + + R S S S 4 + +
77 Lokeshwari 41 F Blood 8 Months + Fever CML NG
Alpha Beta
Gamm
a
Duration 
of illness 
(yrs)
Renal Tx DM CT Symptoms Diagnosis Hemolysin Activity
Carbohydrate Assimilation 
test 
Antifungal 
Susceptiblity Test
Phenotypic Methods - Candida
S.
No.
Name Age Sex Sample
Germ 
Tube 
Test
Chrom Agar Organism Death
Phospholipase ActivityXY MEL RAFFI LAC Suc FLU ITR NYS VOR
Molecular Method Candida
78 Mani 56 M Sputum 4 + Fever Breathlessness
T2 DM / Invasive 
aspergillosis
A.niger
79 Suresh 40 M Br.Wash 5 + Breathlessness Pneumonia A.Fumigatus
80 Varma 38 M B.Wash 3 + Breathlessness Ca. Lung A.Flavus
81 Rani 32 F Urine 2 + Fever ALL - Pink C.Krusei + + - - - - R R S R 3 + +
82 Rekha 34 F Pleural Fluid 6 Months + Breathlessness Ca. Lung NG
83 Sundhar 35 M Br.Wash 1 + Breathlessness/Fever CML NG
84 Selva Kumar 49 M Urine 16 + + Fever Dysuria T2 DM / UTI + Green C.albicans + - - + + R R S R 4 + +
85 Amudha 30 F B.Wash 4 + Breathlessness
T2 DM / (L) LL 
Consolidation
Rhizopus sp +
86 Sharmila 32 F Urine 2 + Fever
NHL / 
Neutropenia
- Blue C.tropicalis + + - - - + R S S S 4 + +
87 Parthiban 29 M Br.Wash 1 + Breathlessness NHL NG
88 Vijay 26 M Br.Wash 1 + Breathlessness Ca.Sigmoid colon NG
89 Kishore 25 M Urine 8 Months + Dysuria T2 DM / UTI NG
90 Viswa 30 M Urine 3 + Dysuria UTI NG
91 Ramya 38 F B.Wash 1 + Breathlessness Ca.Lung A.Flavus
92 Vigneswari 32 F Urine 2 + Dysuria UTI NG
93 Vimala 31 F B.Wash 4 + Breathlessness Pneumonia A.Fumigatus
94 Prakash 40 M Urine 6 + Dysuria UTI NG
95 Sekar 35 M Urine 2 + Fever Dysuria UTI NG
96 Narayanan 36 M Urine 11 + Abdominal Pain UTI NG
97 Vinothini 28 F Pleural Fluid 2 + Breathlessness Ca.Lung NG
98 Vikram 46 M Urine 3 + Fever Breathlessness T2 DM / Spesis - Purple C.glabrata + + - - - - R R S R Negative +
99 Vivek 56 M B.Wash 2 + Breathlessness Pneumonia A.Fumigatus
100 Vinoth Kumar 35 M Urine 6 + Dysuria UTI NG
